Generex Biotechnology (GNBTQ) 10-K 11 Oct 13 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Jul. 31, 2013	Oct. 07, 2013	Jan. 31, 2013
Document And Entity Information
Entity Registrant Name	GENEREX BIOTECHNOLOGY CORP
Entity Central Index Key	1059784
Document Type	10-K
Document Period End Date	31-Jul-13
Amendment Flag	FALSE
Current Fiscal Year End Date	-24
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$19,886,594
Entity Common Stock, Shares Outstanding		599,012,644
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2013

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jul. 31, 2013	Jul. 31, 2012
ASSETS
Cash and cash equivalents	$1,708,954	$246,309
Other current assets	98,315	200,552
Total Current Assets	1,807,269	446,861
Property and Equipment, Net (Note 3)	85,406	704,678
Assets Held for Investment, Net (Note 3)	640,772	858,377
Patents, Net (Note 4)	2,319,416	2,634,458
TOTAL ASSETS	4,852,863	4,644,374
LIABILITIES AND STOCKHOLDERS' (DEFICIENCY)/EQUITY
Accounts payable and accrued expenses (Note 6)	7,661,234	7,015,652
Deferred revenue	224,843	263,125
Current maturities of long-term debt (Note 8)	617,665	1,222,746
Total Current Liabilities	8,503,742	8,501,523
Long-Term Debt, Net (Note 8)		441,415
Derivative Warrant Liability (Note 10)	5,234,293	4,081,627
Derivative Additional Investment Rights Liability (Note 10)	1,256,160
Total Liabilities	14,994,195	13,024,565
Stockholders' Deficiency (Notes 9 and 11):
9% Convertible Preferred Stock
Common stock, $.001 par value; authorized 1,500,000,000 and 750,000,000 shares at July 31, 2013 and 2012, respectively; 580,329,160 and 354,161,297 issued and outstanding at July 31, 2013 and 2012, respectively	580,329	354,161
Additional paid-in capital	356,401,812	348,099,813
Deficit accumulated during the development stage	-367,888,576	-357,611,780
Accumulated other comprehensive income	765,103	777,615
Total Stockholders' Deficiency	-10,141,332	-8,380,191
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	4,852,863	4,644,374
Series A Convertible Preferred Stock
Stockholders' Deficiency (Notes 9 and 11):
9% Convertible Preferred Stock
Series B Convertible Preferred Stock
Stockholders' Deficiency (Notes 9 and 11):
9% Convertible Preferred Stock
Series C Convertible Preferred Stock
Stockholders' Deficiency (Notes 9 and 11):
9% Convertible Preferred Stock
Series D Convertible Preferred Stock
Stockholders' Deficiency (Notes 9 and 11):
9% Convertible Preferred Stock
Series E Convertible Preferred Stock
Stockholders' Deficiency (Notes 9 and 11):
9% Convertible Preferred Stock

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jul. 31, 2013	Jul. 31, 2012
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	750,000,000	1,500,000
Common stock, shares issued	580,329,160	354,161,297
Common stock, shares outstanding	580,329,160	354,161,297
Series A Convertible Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$1,000	$1,000
Convertible preferred stock, shares authorized	5,500	5,500
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%
Series B Convertible Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$1,000	$1,000
Convertible preferred stock, shares authorized	2,000	2,000
Convertible preferred stock, shares issued	0	1,490
Convertible preferred stock, shares outstanding	0	1,490
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%
Series C Convertible Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$1,000	$1,000
Convertible preferred stock, shares authorized	750	0
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%
Series D Convertible Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$1,000	$1,000
Convertible preferred stock, shares authorized	750	0
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%
Series E Convertible Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$1,000	$1,000
Convertible preferred stock, shares authorized	2,450	0
Convertible preferred stock, shares issued	930	0
Convertible preferred stock, shares outstanding	930	0
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended			213 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2013
Income Statement [Abstract]
Revenues, net		$28,651	$291,628	$5,110,784
Cost of Goods Sold		11,109	155,619	1,620,375
Gross profit		17,542	136,009	3,490,409
Operating Expenses:
Research and development	2,192,724	4,987,236	10,250,397	134,168,688
Research and development - related party				220,218
Selling and marketing		165,175	1,025,774	9,333,214
General and administrative	3,936,635	4,889,179	13,392,920	151,738,791
General and administrative - related party				314,328
Total Operating Expenses	6,129,359	10,041,590	24,669,091	295,775,239
Operating Loss	-6,129,359	-10,024,048	-24,533,082	-292,284,830
Other Income (Expense):
Miscellaneous income (expense)			489,292	686,303
Income from assets held for investment, net (Note 3)	1,245,165	2,206,216	349,458	5,579,422
Interest income	353	1,519	6,455	7,782,246
Interest expense	-530,222	-592,525	-208,906	-69,538,904
Change in fair value of derivative liabilities (Note 10)	-3,140,259	-1,081,440	2,220,916	-3,856,236	[1]
Loss on extinguishment of debt				-14,134,068
Net Loss Before Undernoted	-8,554,322	-9,490,278	-21,675,867	-365,766,067
Minority Interest Share of Loss				3,038,185
Net Loss	-8,554,322	-9,490,278	-21,675,867	-362,727,882
Preferred Stock Dividend	1,722,474	376,746	766,417	5,160,694
Net Loss Available to Common Stockholders	($10,276,796)	($9,867,024)	($22,442,284)	($367,888,576)
Basic and Diluted Net Loss Per Common Share (Note 14) (in dollars per share)	($0.02)	($0.03)	($0.08)
Weighted Average Number of Shares of Common Stock Outstanding - basic and diluted (Note 14) (in shares)	443,579,247	332,333,583	284,818,486
[1]	Includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to July 31, 2013" column. See Note 10 - Derivative Liabilities.

STATEMENT_OF_CHANGES_IN_STOCKH

STATEMENT OF CHANGES IN STOCKHOLDERS' (DEFICIENCY)/EQUITY (USD $)	Preferred Stock	Common Stock	Treasury Stock	Additional Paid-In Capital	Notes Receivable Common Stock	Deficit Accumulated During the Development Stage	Accumulated Other Comprehensive Income (Loss)	Total
Balance at Nov. 01, 1995	$0	$0	$0	$0	$0	$0	$0	$0
Balance (in shares) at Nov. 01, 1995	0	0	0
Issuance of common stock for cash	0	4,588	0	2,388,728	0	0	0	2,393,316
Issuance of common stock for cash (in shares)	0	4,587,764	0
Costs related to issuance of common stock (including private placement)	0	0	0	-10,252	0	0	0	-10,252
Founders Shares transferred for services rendered	0	0	0	330,025	0	0	0	330,025
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-693,448	0	-693,448
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	-4,017	-4,017
Total Comprehensive Income (Loss)						-693,448	-4,017	-697,465
Balance at Jul. 31, 1996	0	4,588	0	2,708,501	0	-693,448	-4,017	2,015,624
Balance (in shares) at Jul. 31, 1996	0	4,587,764	0
Issuance of common stock for cash	0	4,412	0	2,916,181	0	0	0	2,920,593
Issuance of common stock for cash (in shares)	0	4,412,354	0
Costs related to issuance of common stock (including private placement)	0	0	0	-135,381	0	0	0	-135,381
Founders Shares transferred for services rendered	0	0	0	23,481	0	0	0	23,481
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-1,379,024	0	-1,379,024
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	3,543	3,543
Total Comprehensive Income (Loss)						-1,379,024	3,543	-1,375,481
Balance at Jul. 31, 1997	0	9,000	0	5,512,782	0	-2,072,472	-474	3,448,836
Balance (in shares) at Jul. 31, 1997	0	9,000,118	0
Shares issued pursuant to reverse merger and acquisition	0	1,105	0	-1,105	0	0	0	0
Shares issued pursuant to reverse merger and acquisition (in shares)	0	1,105,000	0
Issuance of common stock for cash	0	1,174	0	2,931,959	0	0	0	2,933,133
Issuance of common stock for cash (in shares)	0	1,173,253	0
Issuance of common stock in exchange for services rendered	0	458	0	572,727	0	0	0	573,185
Issuance of common stock in exchange for services rendered (in shares)	0	458,901	0
Issuance of warrants in exchange for services rendered	0	0	0	534,000	0	0	0	534,000
Exercise of warrants for cash	0	234	0	15,374	0	0	0	15,608
Exercise of warrants for cash (in shares)	0	234,000	0
Issuance of preferred stock	1	0	0	99	0	0	0	100
Issuance of preferred stock (in shares)	1,000	0	0
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-4,663,604	0	-4,663,604
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	-198,959	-198,959
Total Comprehensive Income (Loss)						-4,663,604	-198,959	-4,862,563
Balance at Jul. 31, 1998	1	11,971	0	9,565,836	0	-6,736,076	-199,433	2,642,299
Balance (in shares) at Jul. 31, 1998	1,000	11,971,272	0
Repurchase of common stock and adjustment for exercise of warrants recorded	0	-324	0	-2,530,301	0	0	0	-2,530,625
Repurchase of common stock and adjustment for exercise of warrants recorded (in shares)	0	-323,920	0
Issuance of common stock for cash	0	1,791	0	7,797,248	0	0	0	7,799,039
Issuance of common stock for cash (in shares)	0	1,790,814	0
Redemption of Stock	0	-15	0	-119,051	0	0	0	-119,066
Redemption of Stock (in shares)	0	-15,357	0
Issuance of common stock in exchange for services rendered	0	314	0	1,349,861	0	0	0	1,350,175
Issuance of common stock in exchange for services rendered (in shares)	0	314,488	0
Issuance of warrants in exchange for services rendered	0	0	0	1,054,374	0	0	0	1,054,374
Issuance of stock options in exchange for services rendered	0	0	0	92,500	0	0	0
Stock adjustment	0	1	0	-1	0	0	0	0
Stock adjustment (in shares)	0	714	0
Exercise of warrants for cash	0	389	0	1,941,484	0	0	0	1,941,873
Exercise of warrants for cash (in shares)	0	388,375	0
Exercise of warrants and stock options in exchange for note receivable	0	95	0	473,787	-473,882	0	0	0
Exercise of warrants and stock options in exchange for note receivable (in shares)	0	94,776	0
Issuance of preferred stock	0	13	0	66,967	0	0	0	66,980
Issuance of preferred stock (in shares)	0	13,396	0
Reduction of note receivable in exchange for services rendered	0	0	0	0	38,979	0	0	38,979
Exercise of warrants for shares tendered	0	506	0	2,530,119	0	0	0	2,530,625
Exercise of warrants for shares tendered (in shares)	0	506,125	0
Cost of warrants redeemed for cash	0	0	0	-3,769	0	0	0	-3,769
Cost related to warrant redemption, June 1999	0	0	0	-135,431	0	0	0	-135,431
Costs related to issuance of common stock (including private placement)	0	0	0	-1,179,895	0	0	0	-1,179,895
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-6,239,602	0	-6,239,602
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	1,393	1,393
Total Comprehensive Income (Loss)						-6,239,602	1,393	-6,238,209
Balance at Jul. 31, 1999	1	14,741	0	20,903,728	-434,903	-12,975,678	-198,040	7,309,849
Balance (in shares) at Jul. 31, 1999	1,000	14,740,683	0
Repurchase of common stock and adjustment for exercise of warrants recorded	0	-2	0	2	0	0	0	0
Repurchase of common stock and adjustment for exercise of warrants recorded (in shares)	0	-2,300	0
Issuance of common stock for cash	0	2	0	14,998	0	0	0	15,000
Issuance of common stock for cash (in shares)	0	2,500	0
Issuance of common stock for cash pursuant to private placement	0	1,513	0	8,248,509	0	0	0	8,250,022
Issuance of common stock for cash pursuant to private placement (in shares)	0	1,512,259	0
Issuance of common stock in exchange for services rendered	0	12	0	66,288	0	0	0	66,300
Issuance of common stock in exchange for services rendered (in shares)	0	12,400	0
Granting of stock options for services rendered	0	0	0	1,065,650	0	0	0	1,065,650
Granting of warrants for services rendered	0	0	0	355,500	0	0	0	355,500
Exercise of warrants for cash	0	61	0	386,190	0	0	0	386,251
Exercise of warrants for cash (in shares)	0	60,791	0
Reduction of note receivable in exchange for services rendered	0	0	0	0	384,903	0	0	384,903
Accrued interest on note receivable	0	0	0	0	-4,118	0	0	-4,118
Costs related to issuance of common stock (including private placement)	0	0	0	-605,799	0	0	0	-605,799
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-8,841,047	0	-8,841,047
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	32,514	32,514
Total Comprehensive Income (Loss)						-8,841,047	32,514	-8,808,533
Balance at Jul. 31, 2000	1	16,327	0	30,435,066	-54,118	-21,816,725	-165,526	8,415,025
Balance (in shares) at Jul. 31, 2000	1,000	16,326,333	0
Issuance of common stock for cash pursuant to private placement	0	3,749	0	40,258,264	0	0	0	40,262,013
Issuance of common stock for cash pursuant to private placement (in shares)	0	3,749,262	0
Issuance of common stock in exchange for services rendered	0	67	0	675,185	0	0	0	675,252
Issuance of common stock in exchange for services rendered (in shares)	0	66,784	0
Issuance of warrants in exchange for equity line agreement	0	0	0	3,406,196	0	0	0	3,406,196
Cashless exercise of warrants	0	12	0	-12	0	0	0	0
Cashless exercise of warrants (in shares)	0	11,718	0
Granting of stock options for services rendered	0	0	0	1,466,900	0	0	0	1,466,900
Issuance of warrants in exchange for services rendered	0	0	0	19,134	0	0	0	19,134
Exercise of warrants for cash	0	312	0	2,256,170	0	0	0	2,256,482
Exercise of warrants for cash (in shares)	0	312,668	0
Exercise of warrants and stock options in exchange for note receivable	0	50	0	249,950	-250,000	0	0	0
Exercise of warrants and stock options in exchange for note receivable (in shares)	0	50,000	0
Accrued interest on note receivable	0	0	0	0	-10,182	0	0	-10,182
Costs related to issuance of common stock (including private placement)	0	0	0	-2,924,939	0	0	0	-2,924,939
Issuance of common stock as employee compensation	0	8	0	100,548	0	0	0	100,556
Issuance of common stock as employee compensation (in shares)	0	8,650	0
Issuance of common stock pursuant to litigation settlement	0	2	0	21,096	0	0	0	21,098
Issuance of common stock pursuant to litigation settlement (in shares)	0	2,832	0
Exercise of stock options for cash	0	148	0	744,852	0	0	0	745,000
Exercise of stock options for cash (in shares)	0	147,500	0
Shares issued for Anti-Dilution Provisions	0	6	0	53,450	0	0	0	53,456
Shares issued for Anti-Dilution Provisions(in shares)	0	5,779	0
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-27,097,210	0	-27,097,210
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	-81,341	-81,341
Total Comprehensive Income (Loss)						-27,097,210	-81,341	-27,178,551
Balance at Jul. 31, 2001	1	20,681	0	76,761,860	-314,300	-48,913,935	-246,867	27,307,440
Balance (in shares) at Jul. 31, 2001	1,000	20,681,526	0
Issuance of warrants in exchange for services rendered	0	0	0	202,328	0	0	0	202,328
Issuance of stock options in exchange for services rendered	0	0	0	157,387	0	0	0
Accrued interest on note receivable	0	0	0	0	-22,585	0	0	-22,585
Issuance of common stock as employee compensation	0	11	0	71,161	0	0	0	71,172
Issuance of common stock as employee compensation (in shares)	0	10,800	0
Preferred stock dividend paid	0	0	0	0	0	-720,900	0	-720,900
Exercise of stock options for cash	0	5	0	27,495	0	0	0	27,500
Exercise of stock options for cash (in shares)	0	5,000	0
Purchase of Treasury Stock for cash	0	0	-395,531	0	0	0	0	-395,531
Purchase of Treasury Stock for cash (in shares)	0	0	-96,500
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-13,693,034	0	-13,693,034
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	-71,185	-71,185
Total Comprehensive Income (Loss)						-13,693,034	-71,185	-13,764,219
Balance at Jul. 31, 2002	1	20,697	-395,531	77,220,231	-336,885	-63,327,869	-318,052	12,862,592
Balance (in shares) at Jul. 31, 2002	1,000	20,697,326	-96,500
Receipt of restricted shares of common stock as settlement for executive loan	0	0	-1,126,157	0	0	0	0	-1,126,157
Receipt of restricted shares of common stock as settlement for executive loan (in shares)	0	0	-592,716
Issuance of common stock for cash pursuant to private placement	0	3,593	0	4,361,657	0	0	0	4,365,250
Issuance of common stock for cash pursuant to private placement (in shares)	0	3,592,968	0
Issuance of common stock in exchange for services rendered	0	100	0	132,900	0	0	0	133,000
Issuance of common stock in exchange for services rendered (in shares)	0	100,000	0
Cashless exercise of warrants	0	16	0	-16	0	0	0	0
Cashless exercise of warrants (in shares)	0	16,379	0
Issuance of warrants in exchange for services rendered	0	0	0	988,550	0	0	0	988,550
Issuance of stock options in exchange for services rendered	0	0	0	171,360	0	0	0	171,360
Exercise of warrants for cash	0	1,531	0	2,294,971	0	0	0	2,296,502
Exercise of warrants for cash (in shares)	0	1,531,001	0
Accrued interest on note receivable	0	0	0	0	-23,113	0	0	-23,113
Costs related to issuance of common stock (including private placement)	0	0	0	-235,568	0	0	0	-235,568
Issuance of common stock as employee compensation	0	10	0	20,665	0	0	0	20,675
Issuance of common stock as employee compensation (in shares)	0	9,850	0
Preferred stock dividend paid	0	0	0	0	0	-764,154	0	-764,154
Exercise of stock options for cash	0	70	0	111,230	0	0	0	111,300
Exercise of stock options for cash (in shares)	0	70,000	0
Purchase of Treasury Stock for cash	0	0	-88,338	0	0	0	0	-88,338
Purchase of Treasury Stock for cash (in shares)	0	0	-53,000
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-13,261,764	0	-13,261,764
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	406,830	406,830
Total Comprehensive Income (Loss)						-13,261,764	406,830	-12,854,934
Balance at Jul. 31, 2003	1	26,017	-1,610,026	85,065,980	-359,998	-77,353,787	88,778	5,856,965
Balance (in shares) at Jul. 31, 2003	1,000	26,017,524	-742,216
Shares issued pursuant to reverse merger and acquisition	0	2,780	0	4,639,777	0	0	0	4,642,557
Shares issued pursuant to reverse merger and acquisition (in shares)	0	2,779,974	0
Cost of stock options to be assumed in conjunction with merger	0	0	0	154,852	0	0	0	154,852
Issuance of common stock for cash pursuant to private placement	0	5,275	0	7,258,727	0	0	0	7,264,002
Issuance of common stock for cash pursuant to private placement (in shares)	0	5,272,916	0
Redemption of Stock	0	-742	1,610,026	-1,609,284	0	0	0	0
Redemption of Stock (in shares)	0	-742,216	742,216
Issuance of common stock in exchange for services rendered	0	776	0	1,346,099	0	0	0	1,346,875
Issuance of common stock in exchange for services rendered (in shares)	0	775,000	0
Granting of stock options for services rendered	0	0	0	151,433	0	0	0	151,433
Issuance of warrants in exchange for services rendered	0	0	0	27,000	0	0	0	27,000
Accrued interest on note receivable	0	0	0	0	-24,805	0	0	-24,805
Costs related to issuance of common stock (including private placement)	0	0	0	-109,262	0	0	0	-109,262
Issuance of common stock as employee compensation	0	8	0	13,089	0	0	0	13,097
Issuance of common stock as employee compensation (in shares)	0	8,850	0
Variable accounting non-cash compensation expense	0	0	0	45,390	0	0	0	45,390
Preferred stock dividend paid	0	0	0	0	0	-810,003	0	-810,003
Exercise of stock options for cash	0	150	0	126,490	0	0	0	126,640
Exercise of stock options for cash (in shares)	0	150,400	0
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-18,362,583	0	-18,362,583
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	207,593	207,593
Total Comprehensive Income (Loss)						-18,362,583	207,593	-18,154,990
Balance at Jul. 31, 2004	1	34,264	0	97,110,291	-384,803	-96,526,373	296,371	529,751
Balance (in shares) at Jul. 31, 2004	1,000	34,262,448	0
Issuance of common stock in exchange for services rendered	0	1,207	0	1,125,317	0	0	0	1,126,524
Issuance of common stock in exchange for services rendered (in shares)	0	1,207,207	0
Granting of stock options for services rendered	0	0	0	92,755	0	0	0	92,755
Cancellation of unissued shares	0	-75	0	-137,925	0	0	0	-138,000
Cancellation of unissued shares (in shares)	0	-75,000	0
Issuance of warrants in conjunction with financing	0	0	0	110,200	0	0	0	110,200
Issuance of warrants in exchange for services rendered	0	0	0	455,000	0	0	0	455,000
Issuance of warrants in conjunction with convertible debentures	0	0	0	4,191,759	0	0	0	4,191,759
Value of beneficial conversion feature on convertible debentures	0	0	0	2,998,032	0	0	0	2,998,032
Conversion of Preferred Stock	0	534	0	14,309,523	0	0	0	14,310,057
Conversion of Preferred Stock (in shares)	0	534,085	0
Issuance of common stock as repayment of principal and interest due	0	1,988	0	1,309,841	0	0	0	1,311,829
Issuance of common stock as repayment of principal and interest due (in shares)	0	1,988,371	0
Issuance of common stock in connection with conversion of Preferred Stock	0	1,976	0	1,478,268	0	0	0	1,480,244
Issuance of common stock in connection with conversion of Preferred Stock (in shares)	0	1,975,881	0
Issuance of common stock in satisfaction of accounts payable	0	1,861	0	1,524,465	0	0	0	1,526,326
Issuance of common stock in satisfaction of accounts payable (in shares)	0	1,861,374	0
Granting of stock options in exchange for outstanding liabilities	0	0	0	1,332,052	0	0	0	1,332,052
Issuance of common stock in conjunction with financing	0	171	0	139,829	0	0	0	140,000
Issuance of common stock in conjunction with financing (in shares)	0	170,732	0
Accrued interest on note receivable	0	0	0	0	-6,300	0	0	-6,300
Write-off of uncollectible notes receivable - common stock	0	0	0	0	391,103	0	0	391,103
Issuance of common stock as employee compensation	0	9	0	4,919	0	0	0	4,928
Issuance of common stock as employee compensation (in shares)	0	8,800	0
Variable accounting non-cash compensation expense	0	0	0	0	0	0	0	0
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-24,001,735	0	-24,001,735
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	272,478	272,478
Total Comprehensive Income (Loss)						-24,001,735	272,478	-23,729,257
Balance at Jul. 31, 2005	1	41,935	0	126,044,326	0	-120,528,108	568,849	6,127,003
Balance (in shares) at Jul. 31, 2005	1,000	41,933,898	0
Issuance of common stock as repayment of monthly amortization payments due	0	3,029	0	4,052,244	0	0	0	4,055,273
Issuance of common stock as repayment of monthly amortization payments due (in shares)	0	3,027,958	0
Issuance of common stock for cash pursuant to private placement	0	3,415	0	6,996,589	0	0	0	7,000,004
Issuance of common stock for cash pursuant to private placement (in shares)	0	3,414,636	0
Issuance of common stock in exchange for services rendered	0	562	0	698,971	0	0	0	699,533
Issuance of common stock in exchange for services rendered (in shares)	0	563,684	0
Cashless exercise of warrants	0	8	0	-8	0	0	0	0
Cashless exercise of warrants (in shares)	0	8,179	0
Issuance of common stock in satisfaction of deposit	0	204	0	255,377	0	0	0	255,581
Issuance of common stock in satisfaction of deposit (in shares)	0	204,465	0
Issuance of warrants in conjunction with financing	0	0	0	210,300	0	0	0	210,300
Issuance of warrants in exchange for services rendered	0	0	0	172,450	0	0	0	172,450
Issuance of warrants in conjunction with convertible debentures	0	0	0	6,732,660	0	0	0	6,732,660
Value of beneficial conversion feature on convertible debentures	0	0	0	6,354,496	0	0	0	6,354,496
Issuance of common stock in connection with conversion of Preferred Stock	0	17,064	0	25,318,448	0	0	0	25,335,512
Issuance of common stock in connection with conversion of Preferred Stock (in shares)	0	17,064,582	0
Issuance of common stock in satisfaction of accounts payable	0	165	0	121,088	0	0	0	121,253
Issuance of common stock in satisfaction of accounts payable (in shares)	0	165,323	0
Issuance of common stock in conjunction with financing	0	662	0	618,805	0	0	0	619,467
Issuance of common stock in conjunction with financing (in shares)	0	661,399	0
Exercise of warrants for cash	0	37,106	0	39,299,959	0	0	0	39,337,065
Exercise of warrants for cash (in shares)	0	37,106,449	0
Issuance of common stock as employee compensation	0	895	0	1,544,609	0	0	0	1,545,504
Issuance of common stock as employee compensation (in shares)	0	895,115	0
Exercise of stock options for cash	0	2,352	0	3,239,404	0	0	0	3,241,756
Exercise of stock options for cash (in shares)	0	2,352,672	0
Issuance of warrants as exercise inducement	0	0	0	21,437,909	0	0	0	21,437,909
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-67,967,204	0	-67,967,204
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	185,232	185,232
Total Comprehensive Income (Loss)						-67,967,204	185,232	-67,781,972
Balance at Jul. 31, 2006	1	107,397	0	243,097,627	0	-188,495,312	754,081	55,463,794
Balance (in shares) at Jul. 31, 2006	1,000	107,398,360	0
Issuance of common stock as repayment of monthly amortization payments due	0	320	0	560,237	0	0	0	560,557
Issuance of common stock as repayment of monthly amortization payments due (in shares)	0	320,266	0
Redemption of Stock	-1	0	0	-99	0	0	0	-100
Redemption of Stock (in shares)	-1,000	0	0
Issuance of common stock in exchange for services rendered	0	613	0	1,041,899	0	0	0	1,042,512
Issuance of common stock in exchange for services rendered (in shares)	0	611,359	0
Cancellation of unissued shares	0	-150	0	150	0	0	0	0
Cancellation of unissued shares (in shares)	0	-150,000	0
Issuance of warrants in exchange for services rendered	0	0	0	266,400	0	0	0	266,400
Issuance of common stock in connection with conversion of Preferred Stock	0	168	0	286,985	0	0	0	287,153
Issuance of common stock in connection with conversion of Preferred Stock (in shares)	0	168,172	0
Exercise of warrants for cash	0	100	0	124,900	0	0	0	125,000
Exercise of warrants for cash (in shares)	0	100,000	0
Issuance of common stock as employee compensation	0	882	0	1,399,694	0	0	0	1,400,576
Issuance of common stock as employee compensation (in shares)	0	881,561	0
Exercise of stock options for cash	0	286	0	301,646	0	0	0	301,932
Exercise of stock options for cash (in shares)	0	286,800	0
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-23,504,958	0	-23,504,958
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	127,726	127,726
Total Comprehensive Income (Loss)						-23,504,958	127,726	-23,377,232
Balance at Jul. 31, 2007	0	109,616	0	247,079,439	0	-212,000,270	881,807	36,070,592
Balance (in shares) at Jul. 31, 2007	0	109,616,518	0
Repurchase of common stock and adjustment for exercise of warrants recorded	0	-326	0	-378,130	0	0	0	-378,456
Repurchase of common stock and adjustment for exercise of warrants recorded (in shares)	0	-326,255	0
Issuance of common stock in exchange for services rendered	0	881	0	1,528,758	0	0	0	1,529,639
Issuance of common stock in exchange for services rendered (in shares)	0	881,444	0
Issuance of restricted common stock to officers as employee compensation	0	550	0	-550	0	0	0	0
Issuance of restricted common stock to officers as employee compensation (in shares)	0	550,000	0
Issuance of warrants in exchange for services rendered	0	0	0	52,500	0	0	0	52,500
Issuance of warrants in conjunction with convertible debentures	0	0	0	10,646,218	0	0	0	10,646,218
Value of beneficial conversion feature on convertible debentures	0	0	0	8,768,946	0	0	0	8,768,946
Issuance of common stock as employee compensation	0	870	0	996,540	0	0	0	997,410
Issuance of common stock as employee compensation (in shares)	0	869,896	0
Stock-based compensation - officers stock options	0	0	0	749,971	0	0	0	749,971
Option repricing costs	0	0	0	14,500	0	0	0	14,500
Exercise of stock options for cash	0	401	0	391,389	0	0	0	391,790
Exercise of stock options for cash (in shares)	0	401,000	0
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-36,228,991	0	-36,228,991
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	32,688	32,688
Total Comprehensive Income (Loss)						-36,228,991	32,688	-36,196,303
Balance at Jul. 31, 2008	0	111,992	0	269,849,581	0	-248,229,261	914,495	22,646,807
Balance (in shares) at Jul. 31, 2008	0	111,992,603	0
Issuance of common stock as repayment of monthly amortization payments due	0	46,590	0	14,444,105	0	0	0	14,490,695
Issuance of common stock as repayment of monthly amortization payments due (in shares)	0	46,590,801	0
Issuance of common stock for cash pursuant to private placement	0	32,583	0	15,420,651	0	0	0	15,453,234
Issuance of common stock for cash pursuant to private placement (in shares)	0	32,582,030	0
Issuance of common stock in exchange for services rendered	0	3,368	0	1,533,068	0	0	0	1,536,436
Issuance of common stock in exchange for services rendered (in shares)	0	3,367,891	0
Cashless exercise of warrants	0	9,909	0	-9,909	0	0	0	0
Cashless exercise of warrants (in shares)	0	9,908,583	0
Issuance of common stock as repayment of principal and interest due	0	1,598	0	502,388	0	0	0	503,986
Issuance of common stock as repayment of principal and interest due (in shares)	0	1,598,472	0
Warrant modification costs	0	0	0	3,198,604	0	0	0	3,198,604
Issuance of common stock in connection with conversion of Preferred Stock	0	4,914	0	1,616,789	0	0	0	1,621,703
Issuance of common stock in connection with conversion of Preferred Stock (in shares)	0	4,914,251	0
Issuance of common stock in satisfaction of accounts payable	0	982	0	437,715	0	0	0	438,697
Issuance of common stock in satisfaction of accounts payable (in shares)	0	982,382	0
Issuance of stock options in exchange for services rendered	0	0	0	11,000	0	0	0
Exercise of warrants for cash	0	330	0	108,839	0	0	0	109,169
Exercise of warrants for cash (in shares)	0	330,817	0
Issuance of common stock as employee compensation	0	262	0	100,740	0	0	0	101,002
Issuance of common stock as employee compensation (in shares)	0	260,984	0
Stock-based compensation - officers stock options	0	0	0	131,545	0	0	0	131,545
Exercise of stock options for cash	0	100	0	55,900	0	0	0	56,000
Exercise of stock options for cash (in shares)	0	100,000	0
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-45,812,228	0	-45,812,228
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	-262,908	-262,908
Total Comprehensive Income (Loss)						-45,812,228	-262,908	-46,075,136
Balance at Jul. 31, 2009	0	212,628	0	307,401,016	0	-294,041,489	651,587	14,223,742
Balance (in shares) at Jul. 31, 2009	0	212,628,814	0
Effect of the initial adoption of accounting for down-round provision	0	0	0	-13,844,822		-5,981,043		-19,825,865
Exercise of warrants classified as derivatives	0	0	0	10,020,557	0	0	0	10,020,557
Issuance of common stock for cash pursuant to private placement	0	35,871	0	20,864,419	0	0	0	20,900,290
Issuance of common stock for cash pursuant to private placement (in shares)	0	35,870,513	0
Issuance of common stock in exchange for services rendered	0	3,064	0	1,752,139	0	0	0	1,755,203
Issuance of common stock in exchange for services rendered (in shares)	0	3,060,659	0
Cashless exercise of warrants	0	7,636	0	-7,635	0	0	0	1
Cashless exercise of warrants (in shares)	0	7,635,626	0
Issuance of warrants in exchange for services rendered	0	0	0	591,000	0	0	0	591,000
Issuance of common stock in satisfaction of accounts payable	0	5,432	0	3,007,164	0	0	0	3,012,596
Issuance of common stock in satisfaction of accounts payable (in shares)	0	5,431,373	0
Issuance of stock options in exchange for services rendered	0	0	0	107,744	0	0	0
Exercise of warrants for cash	0	4,770	0	1,569,292	0	0	0	1,574,062
Exercise of warrants for cash (in shares)	0	4,769,885	0
Option modification costs	0	0	0	875,773	0	0	0	875,773
Issuance of common stock as employee compensation	0	203	0	100,799	0	0	0	101,002
Issuance of common stock as employee compensation (in shares)	0	202,745	0
Stock-based compensation - officers stock options	0	0	0	781,865	0	0	0	781,865
Exercise of stock options for cash (in shares)								0
Comprehensive Income (Loss):
Net loss	0	0	0			-25,279,940		-25,279,940
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	132,596	132,596
Total Comprehensive Income (Loss)						-25,279,940	132,596	-25,147,344
Balance at Jul. 31, 2010	0	269,600	0	333,219,309	0	-325,302,472	784,183	8,970,620
Balance (in shares) at Jul. 31, 2010	0	269,599,615	0
Issuance of common stock for cash pursuant to private placement	0	16,776	0	506,688	0	0	0	523,464
Issuance of common stock for cash pursuant to private placement (in shares)	0	16,776,000	0
Issuance of common stock in exchange for services rendered	0	5,701	0	1,918,305	0	0	0	1,924,006
Issuance of common stock in exchange for services rendered (in shares)	0	5,700,096	0
Cashless exercise of warrants	0	998	0	-998	0	0	0	0
Cashless exercise of warrants (in shares)	0	998,118	0
Issuance of common stock in connection with conversion of Preferred Stock	0	10,910	0	336,850	0	0	0	347,760
Issuance of common stock in connection with conversion of Preferred Stock (in shares)	-1,288	10,909,748	0
Issuance of common stock in satisfaction of accounts payable	0	3,551	0	1,107,315	0	0	0	1,110,866
Issuance of common stock in satisfaction of accounts payable (in shares)	0	3,551,955	0
Issuance of stock options in exchange for services rendered	0	0	0	787,226	0	0	0
Issuance of preferred stock	0
Issuance of preferred stock (in shares)	2,575
Issuance of common stock as employee compensation	0	408	0	100,592	0	0	0	101,000
Issuance of common stock as employee compensation (in shares)	0	407,484	0
Preferred stock dividend paid	0	0	0		0	-766,417	0	-766,417
Stock-based compensation - officers stock options	0	0	0	149,239	0	0	0	149,239
Exercise of stock options for cash	0	577	0	0	0	0	0	577
Exercise of stock options for cash (in shares)	0	576,752	0					-576,752
Comprehensive Income (Loss):
Net loss	0	0	0		0	-21,675,867	0	-21,675,867
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	85,392	85,392
Total Comprehensive Income (Loss)						-21,675,867	85,392	-21,590,475
Balance at Jul. 31, 2011	0	308,520	0	338,124,525	0	-347,744,756	869,575	-8,442,136
Balance (in shares) at Jul. 31, 2011	1,287	308,519,768	0
Issuance of common stock in exchange for services rendered	0	5,401	0	694,044	0	0	0	699,445
Issuance of common stock in exchange for services rendered (in shares)	0	5,401,722	0
Cashless exercise of warrants	0	20,460	0	7,210,274	0	0	0	7,230,734
Cashless exercise of warrants (in shares)	0	20,459,431	0
Issuance of common stock in connection with conversion of Preferred Stock	0	17,299	0	467,891	0	0	0	485,190
Issuance of common stock in connection with conversion of Preferred Stock (in shares)	-1,797	17,299,029	0
Exercise of warrants for cash	0	200	0	29,800	0	0	0	30,000
Exercise of warrants for cash (in shares)	0	200,000	0
Issuance of preferred stock (in shares)	2,000
Issuance of common stock as employee compensation	0	982	0	129,562	0	0	0	130,544
Issuance of common stock as employee compensation (in shares)	0	981,353	0
Preferred stock dividend paid	0	0	0	0	0	-376,746	0	-376,746
Stock-based compensation - officers stock options	0	0	0	602,384	0	0	0	602,384
Exercise of stock options for cash	0	1,300	0	0	0	0	0	1,300
Exercise of stock options for cash (in shares)	0	1,299,994	0					-1,299,994
Exercise of additional investment rights	0	0	0	841,333	0	0	0	841,333
Comprehensive Income (Loss):
Net loss	0	0	0	0	0	-9,490,278	0	-9,490,278
Other comprehensive income (loss)
Currency translation adjustment	0	0	0	0	0	0	-91,961	-91,961
Total Comprehensive Income (Loss)	0	0	0	0	0	-9,490,278	-91,961	-9,582,238
Balance at Jul. 31, 2012	0	354,161	0	348,099,813	0	-357,611,780	777,615	-8,380,191
Balance (in shares) at Jul. 31, 2012	1,490	354,161,297	0
Issuance of common stock in exchange for services rendered		8,251	0	384,171	0	0	0	392,422
Issuance of common stock in exchange for services rendered (in shares)		8,251,500	0
Cashless exercise of warrants		29,185		2,333,431	0	0	0	2,362,616
Cashless exercise of warrants (in shares)		29,184,675
Cancellation of unissued shares		-1,278		1,278	0	0	0	0
Cancellation of unissued shares (in shares)		-1,278,246
Issuance of common stock in connection with conversion of Preferred Stock	0	123,323
Issuance of common stock in connection with conversion of Preferred Stock (in shares)	-3,285	123,323,121	0	1,513,627	0	0	0	3,459,450
Issuance of stock options in exchange for services rendered	0	0	0	802,977	0	0	0	802,977
Exercise of warrants for cash		61,506		3,231,738	0	0	0	3,293,245
Exercise of warrants for cash (in shares)		61,506,785
Issuance of preferred stock (in shares)	2,725
Amortization of options in exchange for services rendered	0	0	0	34,775	0	0	0	34,775
Preferred stock dividend paid				0	0	-1,722,474	0	-1,722,474
Exercise of stock options for cash		5,181		0	0	0	0	5,181
Exercise of stock options for cash (in shares)		5,180,378						-5,180,378
Comprehensive Income (Loss):
Net loss				0	0	-8,554,322	0	-8,554,322
Other comprehensive income (loss)
Currency translation adjustment				0	0	0	-12,512	-12,512
Total Comprehensive Income (Loss)				0	0	-6,880,506	-12,512	-6,893,018
Balance at Jul. 31, 2013	$0	$580,329	$0	$356,401,812	$0	($367,888,576)	$765,103	($10,141,332)
Balance (in shares) at Jul. 31, 2013	930	580,329,160	0

STATEMENT_OF_CHANGES_IN_STOCKH1

STATEMENT OF CHANGES IN STOCKHOLDERS' (DEFICIENCY)/EQUITY [Parenthetical] (USD $)	9 Months Ended	12 Months Ended
In Millions, except Share data, unless otherwise specified	Jul. 31, 1996	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2010	Jul. 31, 2009	Jul. 31, 2008	Jul. 31, 2007	Jul. 31, 2006	Jul. 31, 2005	Jul. 31, 2004	Jul. 31, 2003	Jul. 31, 2002	Jul. 31, 2001	Jul. 31, 2000	Jul. 31, 1999	Jul. 31, 1998	Jul. 31, 1997
Statement Of Changes In Stockholders Deficiencyequity Parenthetical
Issuance of common stock for cash February	$0.03															$5
Issuance of common stock for cash February	$0.05
Issuance of common stock for cash February	$0.51
Issuance of common stock for cash March	$10.24															$6	$2.50	$10.08
Issuance of common stock for cash April	$0.05															$5.50	$2.50
Issuance of common stock for cash May	$0.05															$5.50	$2.50	$0.05
Issuance of common stock for cash May	$0.51																	$0.51
Issuance of common stock for cash May	$10.23																	$10.12
Issuance of common stock for cash July	$0.01																	$10.12
Issuance of common stock for cash July	$0.03
Issuance of common stock for cash July	$0.05
Issuance of common stock for cash July	$10.18
Issuance of common stock for cash September															$6	$3		$0.05
Issuance of common stock for cash December																		$10.24
Issuance of common stock for cash January																		$0.05
Issuance of common stock for cash June																	$2.50	$0.05
Issuance of common stock for cash June																		$0.50
Issuance of common stock for cash June																		$8.98
Issuance of common stock for cash June																		$10.10
Issuance of common stock for services December		$0.03	$0.10	$0.32	$0.50	$0.45	$1.80	$1.68		$0.71							$0.05
Issuance of common stock for services April		$0.15		$0.23	$0.49	$0.30	$1.19	$1.71	$2.67								$2.50
Issuance of common stock for services May				$0.40	$0.38	$0.40	$1.05	$1.60	$1.85							$5.50	$2.50
Issuance of common stock for services June		$0.03		$0.15	$0.35	$0.62	$0.95	$1.40	$1.85	$0.60					$6		$2.50
Issuance of warrants in exchange for services rendered October											$1.35					$0.26	$0.50
Issuance of warrants in exchange for services rendered May								$1.45	$1.91								$0.60
Issuance of common stock for cash August																$3
Issuance of common stock for cash August																$3.50
Issuance of common stock for cash August																$4.10
Issuance of common stock for cash November																$3.50
Issuance of common stock for cash November																$4
Issuance of common stock for cash November																$4.10
Issuance of common stock for cash November																$5
Issuance of common stock for cash November																$5.50
Redemption of common stock for cash September																$7.75
Issuance of common stock for services August		$0.08	$0.11	$0.36	$0.61		$1.57	$1.43	$0.61	$1.09						$2.50
Issuance of common stock for services August			$0.10	$0.38	$0.63				$0.59							$4.10
Issuance of common stock for services September		$0.07	$0.09	$0.41	$0.72	$0.58	$1.48									$4.10
Issuance of common stock for services November			$0.09	$0.31	$0.61	$0.35	$1.71	$2.15	$0.97			$2.10				$4.10
Issuance of common stock for services January		$0.08	$0.15	$0.28	$0.67	$0.34	$1.61	$1.77		$0.85					$5	$5
Issuance of common stock for services February				$0.23	$0.60	$0.27	$1.36	$1.90	$1.53	$0.69	$1.48					$6
Issuance of warrants in exchange for services rendered November												$2.50				$1.64
Issuance of warrants in exchange for services rendered April									$2.66	$0.82						$3.21
Issuance of warrants in exchange for services rendered April																$3.17
Issuance of warrants in exchange for services rendered April																$2.89
Issuance of warrants in exchange for services rendered April																$3.27
Issuance of options in exchange for the services rendered November												$2.10				$1.85
Exercise of warrants for cash June									$1.25			$1.50		$6		$5.50	$0.07
Exercise of warrants in exchange for note receivable June																$5
Exercise of warrants in exchange for services rendered June																$5
Shares tendered in conjunction with warrant exercise June																$7.81
Exercise of warrants for cash June									$1.60							$5
Adjustment for exercise of warrants recorded June															$5
Issuance of common stock for cash pursuant to private placement January				$0.25							$1.47			$14.53	$4.25
Issuance of common stock for cash pursuant to private placement June					$0.35	$0.64			$2.05			$1.50			$6
Exercise of warrants for cash February		$0.00							$0.82						$5.50
Exercise of warrants for cash March		$0.03							$1.72					$6	$5.50
Exercise of warrants for cash March									$1.25						$6
Exercise of warrants for cash March									$0.91						$7.50
Exercise of warrants for cash July		$0.03				$0.33								$6	$6
Exercise of warrants for cash July															$7.50
Issuance of SVR preferred stock in exchange for services rendered January																	$0.00
Exercise of warrants for cash August														$6
Exercise of warrants for cash August														$7.50
Exercise of warrants for cash August														$8.66
Exercise of warrants for cash August														$10
Exercise of warrants for cash September					$0.33									$8.66
Exercise of warrants for cash September														$5.50
Exercise of warrants for cash September														$6
Exercise of warrants for cash September														$10
Exercise of warrants for cash September														$7.50
Exercise of warrants for cash October								$1.25	$0.82					$6
Exercise of warrants for cash November									$0.82					$4.25
Exercise of warrants for cash November														$6
Exercise of warrants for cash December														$7
Exercise of warrants for cash January		$0.03	$0.15						$0.82					$6
Issuance of common stock for services March		$0.00		$0.21	$0.64	$0.29	$1	$1.71	$2.31			$1		$5.50
Issuance of common stock for services July		$0.15	$0.15	$0.14	$0.33	$0.38	$0.79	$1.78	$1.40					$9.25
Issuance of common stock for cash pursuant to private placement October														$11
Issuance of common stock for cash pursuant to private placement July											$1.22			$9.25
Exercise of stock options for cash February							$1		$0.94					$5
Exercise of stock options for cash June												$1.59		$5
Exercise of stock options for cash June														$5.50
Exercise of stock options for cash July		$0.00	$0.00					$0.94						$5
Exercise of stock options for cash July								$0.56						$5.50
Exercise of stock options for cash August						$0.56							$5.50
Purchase of Treasury Stock for cash October												$1.56	$3.92
Purchase of Treasury Stock for cash February													$4.69
Purchase of Treasury Stock for cash March													$4.91
Purchase of Treasury Stock for cash April													$4.03
Purchase of Treasury Stock for cash July													$4.03
Receipt of restricted shares of common stock as settlement for executive loan September												$1.90
Purchase of Treasury Stock for cash December												$2.00
Issuance of common stock as employee compensation January				$0.28	$0.64	$0.34						$2.10
Issuance of common stock as employee compensation June			$0.15	$0.17	$0.33	$0.57	$0.97					$2
Issuance of common stock for cash pursuant to private placement May					$0.35	$0.33						$1.15
Exercise of warrants for cash May												$1.50
Redemption of Treasury Stock November											$2.17
Issuance of common stock as employee compensation February				$0.23	$0.60	$0.23	$1.32				$1.48
Exercise of stock options for cash September											$1.59
Exercise of stock options for cash October								$1.59	$0.63		$2.10
Exercise of stock options for cash October								$1.47	$0.94		$1.59
Exercise of stock options for cash October											$0.30
Exercise of stock options for cash October											$0.55
Exercise of stock options for cash November								$1.59	$0.94		$2.10
Issuance of common stock for services October		$0.15		$0.37	$0.68	$0.32	$1.50	$1.50			$1.98
Issuance of common stock for services October		$0.06		$0.45	$0.70		$1.53	$1.83			$1.84
Issuance of common stock for services February				$0.24	$0.59		$1.34			$0.68	$1.51
Issuance of common stock for cash pursuant to private placement January											$1.80
Issuance of common stock for cash pursuant to private placement January											$1.75
Issuance of common stock for cash pursuant to private placement February											$1.60
Issuance of common stock for cash pursuant to private placement February											$1.66
Issuance of common stock for cash pursuant to private placement February											$1.50
Issuance of common stock for services January		$0.15		$0.25	$0.59	$0.33	$1.38			$0.75
Cancellation of common stock for non-performance of services October										$0.94
Conversion of Series A Preferred Stock December										$25.77
Issuance of common stock as employee compensation April			$0.15	$0.22	$0.46	$0.37	$1.08	$1.64		$0.56
Granting of stock options in exchange for outstanding liabilities April										$0.00
Issuance of common stock in conjunction with financing June (in dollars)										$20,000
Issuance of warrants in exchange for services rendered August										$1.08
Granting of stock options in exchange for services October										$0.94
Granting of stock options in exchange for services July										$0.63
Issuance of warrants in conjunction with financing November										$0.91
Issuance of warrants in conjunction with financing June (in dollars)										20,000
Issuance of warrants in conjunction with financing June										$0.82
Issuance of warrants in conjunction with convertible debentures November (in dollars)										40,000
Issuance of warrants in conjunction with convertible debentures November										$0.91
Issuance of warrants in conjunction with convertible debentures April (in dollars)										5,000
Issuance of warrants in conjunction with convertible debentures April										$0.82
Issuance of warrants in conjunction with convertible debentures April (in dollars)										1,000
Issuance of warrants in conjunction with convertible debentures June (in dollars)										20,000
Issuance of warrants in conjunction with convertible debentures June										$0.82
Issuance of warrants in conjunction with extension of due date of convertible debentures May (in dollars)										6,000
Issuance of warrants in conjunction with extension of due date of convertible debentures May										$0.82
Issuance of warrants in conjunction with extension of due date of convertible debentures July (in dollars)										6,000
Issuance of warrants in conjunction with extension of due date of convertible debentures July										$0.82
Value of beneficial conversion feature on convertible debentures November (in dollars)									40,000	40,000
Value of beneficial conversion feature on convertible debentures November										$0.91
Value of beneficial conversion feature on convertible debentures April (in dollars)									40,000	5,000
Value of beneficial conversion feature on convertible debentures April										$0.82
Value of beneficial conversion feature on convertible debentures April (in dollars)										1,000
Value of beneficial conversion feature on convertible debentures June (in dollars)										20,000
Value of beneficial conversion feature on convertible debentures June										$0.82
Issuance of common stock as repayment of principal and interest due February (in dollars)										40,000
Issuance of common stock as repayment of principal and interest due March (in dollars)										40,000
Issuance of common stock as repayment of principal and interest due April (in dollars)										40,000
Issuance of common stock as repayment of principal and interest due May (in dollars)										40,000
Issuance of common stock as repayment of principal and interest due June (in dollars)										40,000
Issuance of common stock as repayment of principal and interest due July (in dollars)										40,000
Issuance of common stock in connection with conversion of debenture April (in dollars)								525.54	3,076.92	1,435
Issuance of common stock in connection with conversion of debenture April (in dollars)								40,000	20,000	40,000
Issuance of common stock in connection with conversion of debenture May (in dollars)										3,000
Issuance of common stock in connection with conversion of debenture May (in dollars)										40,000
Issuance of common stock in connection with conversion of debenture May (in dollars)										2,440
Issuance of common stock in connection with conversion of debenture May (in dollars)										4,100
Issuance of common stock in connection with conversion of debenture June (in dollars)										1,000
Issuance of common stock in connection with conversion of debenture June (in dollars)										20,000
Issuance of common stock in connection with conversion of debenture June (in dollars)										1,900
Issuance of common stock in connection with conversion of debenture July (in dollars)										170
Issuance of common stock in connection with conversion of debenture July (in dollars)										20,000
Issuance of common stock in connection with conversion of debenture July (in dollars)										750
Issuance of common stock in satisfaction of accounts payable April										$0.82
Issuance of common stock in satisfaction of accounts payable June										$0.82
Issuance of common stock in satisfaction of accounts payable July										$0.82
Cashless Exercise of warrants March									$2.50
Issuance of common stock in satisfaction of deposit April									$1.25
Issuance of common stock as repayment of monthly amortization payments due August (in dollars)									40,000
Issuance of common stock as repayment of monthly amortization payments due September (in dollars)									40,000
Issuance of common stock as repayment of monthly amortization payments due September (in dollars)									20,000
Issuance of common stock as repayment of monthly amortization payments due October (in dollars)									40,000
Issuance of common stock as repayment of monthly amortization payments due October (in dollars)									20,000
Issuance of common stock as repayment of monthly amortization payments due November (in dollars)									40,000
Issuance of common stock as repayment of monthly amortization payments due November									$1.17
Issuance of common stock as repayment of monthly amortization payments due November (in dollars)									20,000
Issuance of common stock as repayment of monthly amortization payments due December (in dollars)									20,000
Issuance of common stock as repayment of monthly amortization payments due December									$0.98
Issuance of common stock as repayment of monthly amortization payments due January (in dollars)									20,000
Issuance of common stock as repayment of monthly amortization payments due January									$0.81
Issuance of common stock as repayment of monthly amortization payments due January (in dollars)									5,000
Issuance of common stock as repayment of monthly amortization payments due February (in dollars)								40,000	5,000
Issuance of common stock as repayment of monthly amortization payments due February								$1.48	$1.23
Issuance of common stock as repayment of monthly amortization payments due February (in dollars)									20,000
Issuance of common stock as repayment of monthly amortization payments due March (in dollars)									20,000
Issuance of common stock as repayment of monthly amortization payments due March									$2.31
Issuance of common stock as repayment of monthly amortization payments due March (in dollars)									5,000
Issuance of common stock as repayment of monthly amortization payments due March (in dollars)									35,000
Issuance of common stock as repayment of monthly amortization payments due April (in dollars)									20,000
Issuance of common stock as repayment of monthly amortization payments due April									$2.70
Issuance of common stock as repayment of monthly amortization payments due April (in dollars)									35,000
Issuance of common stock as repayment of monthly amortization payments due January (in dollars)									40,000
Issuance of common stock as repayment of monthly amortization payments due January									$2.70
Issuance of common stock as repayment of monthly amortization payments due January									$3.10
Issuance of common stock as repayment of monthly amortization payments due February (in dollars)									40,000
Issuance of common stock as repayment of monthly amortization payments due February								$1.53	$3.10
Issuance of common stock as repayment of monthly amortization payments due January									$1.96
Issuance of common stock as repayment of monthly amortization payments due February								$1.65	$1.96
Issuance of common stock as repayment of monthly amortization payments due January									$1.75
Issuance of common stock as repayment of monthly amortization payments due February								$2.02	$1.75
Issuance of common stock for services August									$0.97
Issuance of common stock for services March				$0.24	$0.62	$0.30	$0.95	$1.65	$2.96
Issuance of common stock for services May				$0.23	$0.33	$0.38	$0.97	$1.47	$1.88
Issuance of common stock in connection with conversion of debenture September (in dollars)									5,045.38
Issuance of common stock in connection with conversion of debenture September (in dollars)									20,000
Issuance of common stock in connection with conversion of debenture September (in dollars)									2,865.38
Issuance of common stock in connection with conversion of debenture September (in dollars)									4,572
Issuance of common stock in connection with conversion of debenture September (in dollars)									2,115.38
Issuance of common stock in connection with conversion of debenture September (in dollars)									1,500
Issuance of common stock in connection with conversion of debenture September (in dollars)									4,573.17
Issuance of common stock in connection with conversion of debenture October (in dollars)									3,073.17
Issuance of common stock in connection with conversion of debenture October (in dollars)									20,000
Issuance of common stock in connection with conversion of debenture October (in dollars)									3,000
Issuance of common stock in connection with conversion of debenture October (in dollars)									5,000
Issuance of common stock in connection with conversion of debenture October (in dollars)									1,130.77
Issuance of common stock in connection with conversion of debenture October (in dollars)									2,976.92
Issuance of common stock in connection with conversion of debenture October (in dollars)									40,000
Issuance of common stock in connection with conversion of debenture October (in dollars)									1,000
Issuance of common stock in connection with conversion of debenture November (in dollars)								525.54	428
Issuance of common stock in connection with conversion of debenture November (in dollars)								40,000	20,000
Issuance of common stock in connection with conversion of debenture November									$1.23
Issuance of common stock in connection with conversion of debenture November (in dollars)									2,307.69
Issuance of common stock in connection with conversion of debenture November (in dollars)									40,000
Issuance of common stock in connection with conversion of debenture November									$0.97
Issuance of common stock in connection with conversion of debenture December (in dollars)									14,510
Issuance of common stock in connection with conversion of debenture December (in dollars)									35,000
Issuance of common stock in connection with conversion of debenture December									$0.93
Issuance of common stock in connection with conversion of debenture December (in dollars)									42.21
Issuance of common stock in connection with conversion of debenture December (in dollars)									20,000
Issuance of common stock in connection with conversion of debenture December									$0.85
Issuance of common stock in connection with conversion of debenture December (in dollars)									820
Issuance of common stock in connection with conversion of debenture December									$0.84
Issuance of common stock in connection with conversion of debenture January (in dollars)									6,170
Issuance of common stock in connection with conversion of debenture January (in dollars)									35,000
Issuance of common stock in connection with conversion of debenture January									$0.94
Issuance of common stock in connection with conversion of debenture January (in dollars)									8,500
Issuance of common stock in connection with conversion of debenture January									$1.06
Issuance of common stock in connection with conversion of debenture February (in dollars)									9,500
Issuance of common stock in connection with conversion of debenture February (in dollars)									40,000
Issuance of common stock in connection with conversion of debenture February									$2.38
Issuance of common stock in connection with conversion of debenture March (in dollars)									15,500
Issuance of common stock in connection with conversion of debenture March (in dollars)									40,000
Issuance of common stock in connection with conversion of debenture March									$2.21
Issuance of common stock in connection with conversion of debenture March (in dollars)									23,500
Issuance of common stock in connection with conversion of debenture March									$2.31
Issuance of common stock in connection with conversion of debenture March (in dollars)									5,000
Issuance of common stock in connection with conversion of debenture March									$2.20
Issuance of common stock in connection with conversion of debenture March (in dollars)									2,000
Issuance of common stock in connection with conversion of debenture March (in dollars)									3,846.15
Issuance of common stock in connection with conversion of debenture March								$1.71	$3.33
Issuance of common stock in connection with conversion of debenture April								$1.61	$2.63
Issuance of common stock in connection with conversion of debenture April (in dollars)									4,230.77
Issuance of common stock in connection with conversion of debenture April (in dollars)									35,000
Issuance of common stock in connection with conversion of debenture April (in dollars)									9,230.77
Issuance of common stock in connection with conversion of debenture April (in dollars)									40,000
Issuance of common stock in satisfaction of accounts payable September									$0.81
Issuance of common stock in satisfaction of accounts payable March									$3.20
Issuance of common stock in conjunction with financing September (in dollars)									20,000
Issuance of common stock in conjunction with financing September									$0.82
Issuance of common stock in conjunction with financing December (in dollars)									35,000
Issuance of common stock in conjunction with financing December									$0.95
Issuance of common stock in conjunction with financing January (in dollars)									40,000
Issuance of common stock in conjunction with financing January									$1
Issuance of warrants in conjunction with financing September (in dollars)									20,000
Issuance of warrants in conjunction with financing September									$0.82
Issuance of warrants in conjunction with financing October (in dollars)									5,000
Issuance of warrants in conjunction with financing October									$0.82
Issuance of common stock in conjunction with financing December									$0.82
Issuance of common stock in conjunction with financing January									$1.05
Issuance of warrants in conjunction with convertible debentures September (in dollars)									20,000
Issuance of warrants in conjunction with convertible debentures September									$0.82
Issuance of warrants in conjunction with convertible debentures October (in dollars)									5,000
Issuance of warrants in conjunction with convertible debentures October									$0.82
Issuance of warrants in conjunction with convertible debentures December (in dollars)									35,000
Issuance of warrants in conjunction with convertible debentures December									$0.82
Issuance of warrants in conjunction with convertible debentures January (in shares)									4,000,000
Issuance of warrants in conjunction with convertible debentures January									$1.05
Issuance of warrants in conjunction with convertible debentures February (in shares)									4,000,000
Issuance of warrants in conjunction with convertible debentures February									$1.05
Value of Beneficial Conversion Feature on Convertible Debentures September (in dollars)									20,000
Value of Beneficial Conversion Feature on Convertible Debentures September									$0.82
Value of Beneficial Conversion Feature on Convertible Debentures October (in dollars)									5,000
Value of Beneficial Conversion Feature on Convertible Debentures October									$0.82
Value of Beneficial Conversion Feature on Convertible Debentures December (in dollars)									35,000
Value of Beneficial Conversion Feature on Convertible Debentures December									$0.82
Value of Beneficial Conversion Feature on Convertible Debentures January									$1.05
Value of Beneficial Conversion Feature on Convertible Debentures February									$1.05
Exercise of warrants for cash February									$1.05
Exercise of warrants for cash February									$1.20
Exercise of warrants for cash February									$1.25
Exercise of warrants for cash February									$1.72
Exercise of warrants for cash March									$0.82
Exercise of warrants for cash March									$1.05
Exercise of warrants for cash March									$1.68
Exercise of warrants for cash March									$2.15
Exercise of warrants for cash March									$1.88
Exercise of warrants for cash March									$2.02
Exercise of warrants for cash March									$1.86
Exercise of warrants for cash April					$0.33				$1.88
Exercise of warrants for cash April									$0.82
Exercise of warrants for cash April									$0.91
Exercise of warrants for cash April									$1.05
Exercise of stock options for cash November									$0.63
Exercise of stock options for cash January		$0.00		$0.00					$0.63
Exercise of stock options for cash February									$1.59
Exercise of stock options for cash February									$1.38
Exercise of stock options for cash March									$0.94
Exercise of stock options for cash March									$1.47
Exercise of stock options for cash March									$1.59
Exercise of stock options for cash March									$1.71
Exercise of stock options for cash March									$2.10
Exercise of stock options for cash March									$1.10
Exercise of stock options for cash March									$1.52
Exercise of stock options for cash March									$2.19
Exercise of stock options for cash March									$0.63
Exercise of stock options for cash April							$1		$1.47
Exercise of stock options for cash April							$0.89		$0.94
Exercise of stock options for cash May								$0.63	$2.10
Exercise of stock options for cash May									$1.47
Issuance of warrants as exercise inducement October									$1.20
Issuance of warrants as exercise inducement October									$1.25
Issuance of warrants as exercise inducement December									$1.25
Issuance of warrants as exercise inducement January									$1.60
Issuance of warrants as exercise inducement February									$3
Issuance of warrants as exercise inducement March									$3
Issuance of warrants as exercise inducement June									$2.35
Issuance of common stock as employee compensation December				$0.29	$0.56	$0.38	$1.75		$0.90
Issuance of common stock as employee compensation May				$0.21	$0.38	$0.38	$1	$1.45	$1.88
Issuance of warrants in exchange for services rendered March					$1.25		$3.75	$1.71
Cancellation of common stock May								$1.45
Issuance of common stock for services March					$0.53	$0.35	$1.14	$1.69
Issuance of common stock for services April		$0.03		$0.22	$0.53	$0.39	$1.06	$1.65
Issuance of common stock for services April					$0.47	$0.33		$1.69
Issuance of common stock for services June				$0.18	$0.32	$0.64		$1.83
Issuance of common stock for services July		$0.03		$0.13	$0.35	$0.58	$0.80	$1.75
Issuance of common stock for services July				$0.15	$0.40	$0.56		$1.68
Issuance of common stock for services June						$0.42		$1.80
Issuance of common stock as employee compensation October				$0.36	$0.60	$0.31	$1.52	$1.83
Issuance of common stock as employee compensation March				$0.25	$0.56	$0.31	$1.04	$1.71
Issuance of common stock as employee compensation March								$1.70
Issuance of common stock as employee compensation July				$0.13	$0.35	$0.66	$0.83	$1.78
Issuance of common stock as employee compensation April								$1.65
Issuance of common stock in connection with conversion of debenture January								$1.74
Issuance of common stock in connection with conversion of debenture January								$1.77
Issuance of common stock in connection with conversion of debenture March (in dollars)								525.54
Issuance of common stock in connection with conversion of debenture March (in dollars)								40,000
Issuance of warrants as employee compensation March							$0.94
Issuance of warrants in conjunction with convertible debentures March							$1.10
Issuance of warrants in conjunction with convertible debentures March							$1.21
Repurchase of common stock March							$1.16
Value of Beneficial Conversion Feature on Convertible Debentures March							$1.21
Issuance of common stock for services September				$0.45	$0.62	$0.53	$1.61
Issuance of common stock for services September				$0.49	$0.76		$1.53
Issuance of common stock for services November				$0.30	$0.51	$0.38	$1.75
Issuance of common stock for services November					$0.45		$1.54
Issuance of common stock for services November							$1.53
Issuance of common stock for services December				$0.30	$0.56	$0.47	$1.84
Issuance of common stock for services December				$0.29	$0.61	$0.53	$1.74
Issuance of common stock for services January		$0.06			$0.62		$1.34
Issuance of common stock as employee compensation August			$0.10	$0.43	$0.62	$0.56	$1.51
Issuance of common stock as employee compensation August							$1.50
Issuance of common stock as employee compensation September			$0.10	$0.50	$0.73	$0.56	$1.55
Issuance of common stock as employee compensation October							$1.53
Issuance of common stock as employee compensation November				$0.31	$0.50	$0.35	$1.70
Issuance of common stock as employee compensation October							$1.36
Stock-based compensation - officers stock options May							$0.96
Exercise of stock options for cash December							$1.59
Issuance of options in exchange for the services rendered May					$0.46	$0.29
Issuance of common stock in satisfaction of accounts payable June				$0.19	$0.33	$0.36
Issuance of common stock in satisfaction of accounts payable June				$0.23	$0.37	$0.65
Issuance of common stock as converstion of Convertible Notes June						$0.33
Issuance of common stock as repayment of monthly amortization payments on convertible notes August						$0.65
Issuance of common stock as repayment of monthly amortization payments on convertible notes September						$0.52
Issuance of common stock as repayment of monthly amortization payments on convertible notes October						$0.29
Issuance of common stock as repayment of monthly amortization payments on Convertible Notes November						$0.29
Issuance of common stock as repayment of monthly amortization payments on Convertible Notes January						$0.32
Issuance of common stock as repayment of monthly amortization payments on Convertible Notes March						$0.18
Issuance of common stock as repayment of monthly amortization payments on Convertible Notes April						$0.28
Issuance of common stock as repayment of monthly amortization payments on Convertible Notes April						$0.30
Issuance of common stock as repayment of monthly amortization payments on Convertible Notes May						$0.33
Issuance of common stock for services May			$0.10	$0.22	$0.39	$0.37
Issuance of common stock for services May				$0.21		$0.42
Issuance of common stock for services June						$0.43
Issuance of common stock for services June						$0.76
Issuance of common stock for services June						$0.58
Issuance of common stock for services April			$0.10		$0.45	$0.65
Issuance of common stock for services July			$0.09			$0.62
Issuance of common stock in exchange for the services rendered March					$0.60	$0.31
Issuance of common stock as repayment of interest on Convertible Notes October						$0.52
Issuance of common stock as repayment of interest on Convertible Notes March						$0.18
Issuance of common stock as repayment of interest on Convertible Notes May						$0.33
Cashless Exercise of warrants April					$0.33	$0.50
Cashless Exercise of warrants June						$0.33
Issuance of common stock for cash pursuant to private placement June						$0.33
Issuance of common stock for cash pursuant to private placement August					$0.79
Issuance of common stock for cash pursuant to private placement September					$0.80
Issuance of common stock for cash pursuant to private placement April					$0.47
Issuance of common stock for cash pursuant to private placement April					$0.43
Issuance of common stock for cash pursuant to private placement April					$0.42
Issuance of common stock for services October			$0.09	$0.40	$0.65
Issuance of common stock for services October				$0.34	$0.53
Issuance of common stock for services December				$0.31	$0.57
Issuance of common stock for services December					$0.53
Issuance of common stock for services January					$0.63
Issuance of common stock for services February			$0.15		$0.63
Issuance of common stock for services March					$0.54
Cashless Exercise of warrants January					$0.33
Issuance of options in exchange for the services rendered December				$0.64	$0.46
Issuance of options in exchange for the services rendered March				$0.28	$0.64
Issuance of options in exchange for the services rendered July		$0.00			$0.38
Issuance of common stock in satisfaction of accounts payable September				$0.36	$0.55
Issuance of common stock in satisfaction of accounts payable September				$0.49	$0.77
Issuance of common stock in satisfaction of accounts payable December				$0.29	$0.48
Issuance of common stock in satisfaction of accounts payable December				$0.33	$0.67
Issuance of common stock in satisfaction of accounts payable March					$0.45
Issuance of common stock in satisfaction of accounts payable March					$0.65
Issuance of warrants in exchange for services rendered December					$0.51
Cashless Exercise of warrants September				$0.00
Issuance of common stock in connection with conversion of Preferred Stock July (in dollars)				12,880
Convertible Preferred Stock Original Amount in July (in dollars)				25,750
Issuance of options in exchange for the services rendered September				$0.64
Issuance of options in exchange for the services rendered March				$0.64
Issuance of options in exchange for the services rendered June		$0.00		$0.64
Issuance of common stock for cash pursuant to private placement March				$0.25
Issuance of common stock in connection with conversion of Series A Preferred Stock Sep			7,870
Issuance of common stock in connection with conversion of Series A Preferred Stock Dec			5,000
Issuance of common stock in connection with conversion of Series B Preferred Stock Jun			5,100
Convertible Preferred Stock Original Amoun in Jun			20,000
Issuance of common stock in connection with conversion of Series B Preferred Stock		14.9
Issuance of common stock in connection with conversion of Preferred Stock, par value		$1,000
Issuance of common stock in connection with conversion of Series C Preferred Stock		7.5
Issuance of common stock in connection with conversion of Series D Preferred Stock		7.5
Issuance of common stock in connection with conversion of Series E Preferred Stock		$2.95
Issuance of options in exchange for the services rendered February		$0.00			$0.38
Issuance of options in exchange for the services rendered April		$0.00

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended			213 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2013
Cash Flows From Operating Activities:
Net loss	($8,554,322)	($9,490,278)	($21,675,867)	($362,727,882)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	463,718	612,658	742,961	10,372,258
Minority interest share of loss				-3,038,185
Reduction of notes receivable - common stock in exchange for services rendered				423,882
Write-off of uncollectible notes receivable - common stock				391,103
Write-off of deferred offering costs				3,406,196
Write-off of abandoned patents		440,780		1,353,976
(Gain)/loss on disposal of property and equipment	-1,037,485	-2,027,939	35,878	-3,028,635
Loss on extinguishment of debt				14,134,068
Common stock issued as employee compensation				4,011,938
Amortization of options and option modifications as stock compensation	837,754	602,384	936,465	4,248,980
Common stock issued for services rendered	392,421	699,445	1,990,005	14,899,700
Amortization of prepaid services in conjunction with common stock issuance				138,375
Non-cash compensation expense				45,390
Stock options and warrants issued for services rendered				7,956,723
Issuance of warrants as additional exercise right inducement				21,437,909
Preferred stock issued for services rendered				100
Treasury stock redeemed for non-performance of services				-138,000
Amortization of deferred debt issuance costs and loan origination fees				2,405,629
Amortization of discount on convertible debentures				38,345,592
Common stock issued for interest on convertible debentures & preferred stock	886,950	485,190		2,129,654
Interest on short-term advance				22,190
Founders' shares transferred for services rendered				353,506
Fees in connection with refinancing of debt				113,274
Warrant repricing costs				3,198,604
Change in fair value of derivative liabilities	3,140,259	1,081,440	-2,220,916	3,856,236	[1]
Changes in operating assets and liabilities (excluding the effects of acquisition):
Accounts receivable		8,470	62,200	-15,047
Miscellaneous receivables				-43,812
Inventory		716,392	1,197,768	-20,091
Other current assets	124,197	20,946	116,171	-58,751
Accounts payable and accrued expenses	123,556	-1,218,616	1,811,120	15,147,496
Deferred revenue	-38,282	-105,395	-28,152	219,050
Other, net				110,317
Net Cash Used in Operating Activities	-3,661,234	-8,043,979	-16,931,368	-220,260,632
Cash Flows From Investing Activities:
Purchase of property and equipment		-2,416	-52,383	-4,809,439
Proceeds from sale of property and equipment	1,764,008	4,953,325		6,717,333
Costs incurred for patents	-78,948	-173,775	-234,984	-2,918,994
Change in restricted cash				-512,539
Proceeds from maturity of short term investments				195,242,918
Purchases of short-term investments				-195,242,918
Cash received in conjunction with merger				82,232
Advances to Antigen Express, Inc.				-32,000
Increase in officers' loans receivable				-1,126,157
Change in deposits				-652,071
Change in notes receivable - common stock				-91,103
Change in due from related parties				-2,222,390
Other, net				89,683
Net Cash Provided By (Used in) Investing Activities	1,685,060	4,777,134	-287,367	-4,450,367
Cash Flows From Financing Activities:
Proceeds from short-term advance				325,179
Repayment of short-term advance				-347,369
Proceeds from issuance of long-term debt	829,038	3,561,688		6,396,335
Repayment of long-term debt	-1,833,265	-4,821,511	-116,632	-8,895,964
Repayment of obligations under capital lease			-7,818	-83,002
Change in due to related parties				154,541
Proceeds from exercise of warrants	1,845,204	30,000		47,573,485
Proceeds from exercise of stock options	5,181	1,300	577	5,008,974
Proceeds from minority interest investment				3,038,185
Proceeds from issuance of preferred stock	2,615,000	1,975,000	2,315,000	18,920,000
Redemption of SVR preferred stock				-100
Proceeds from issuance of convertible debentures, net				40,704,930
Payment of costs associated with convertible debentures				-722,750
Repayments of convertible debentures				-5,142,424
Purchase of treasury stock				-483,869
Proceeds from issuance of common stock, net			3,939,000	120,576,242
Purchase and retirement of common stock				-497,522
Net Cash Provided by Financing Activities	3,461,158	746,477	6,130,127	226,524,871
Effect of Exchange Rates on Cash	-22,339	-32,120	6,535	-104,918
Net (Decrease) Increase in Cash and Cash Equivalents	1,462,645	-2,552,488	-11,082,073	1,708,954
Cash and Cash Equivalents, Beginning of Period	246,309	2,798,797	13,880,870
Cash and Cash Equivalents, End of Period	$1,708,954	$246,309	$2,798,797	$1,708,954
[1]	Includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to July 31, 2013" column. See Note 10 - Derivative Liabilities.

Organization_and_Business

Organization and Business	12 Months Ended
	Jul. 31, 2013
Accounting Policies [Abstract]
Organization and Business	Note 1 - Organization and Business:
	Generex Biotechnology Corporation (the Company) and its wholly-owned subsidiary Generex Pharmaceuticals, Inc. are engaged in the research and development of drug delivery systems and technology. Since its inception, the Company has devoted its efforts and resources to the development of a platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones and vaccines, which historically have been administered by injection, either subcutaneously or intravenously. Oral-lynTM the first product based on this platform technology, is in various stages of regulatory approval in different jurisdictions around the world.
	The Company’s wholly-owned subsidiary, Antigen Express, Inc. (Antigen), is engaged in research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune and allergic diseases.  The Company’s immunomedicine products work by stimulating the immune system to either attack offending agents (i.e., cancer cells, bacteria, and viruses) or to stop attacking benign elements (i.e., self proteins and allergens). The immunomedicine products are based on two platform technologies that were discovered by an executive officer of Antigen, the Ii-Key hybrid peptides and Ii-Suppression. These technologies are expected to greatly boost immune cell responses which diagnose and treat the ailments and conditions.
	The Company is a development stage company, which has a limited history of operations and limited revenue to date. This revenue has been comprised mainly of the sale of our confectionary products, although the Company has recognized $600,000 relating to upfront license fees for the signing of license and distribution agreements for Generex Oral-lyn™. Additionally, the Company has several product candidates that are in various research or early stages of pre-clinical and clinical development. There can be no assurance that the Company will be successful in obtaining regulatory clearance for the sale of existing or any future products or that any of the Company’s products will be commercially viable.

Going_Concern

Going Concern	12 Months Ended
	Jul. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Going Concern
	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has experienced negative cash flows from operations since inception and has an accumulated deficit of approximately $368 million and a working capital deficiency of approximately $6.7 million at July 31, 2013. The Company has funded its activities to date almost exclusively from debt and equity financings, as well as the recent sales of non-essential real estate assets in fiscal 2012, fiscal 2013 and the beginning of fiscal 2014.
	The Company will continue to require substantial funds to continue research and development, including pre-clinical studies and clinical trials of its product candidates, and to commence sales and marketing efforts, if the U.S. Food and Drug Administration or other regulatory approvals are obtained.  Management’s plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common stock, preferred stock offerings, issuances of debt and convertible debt instruments.  Management will be limited in the financing activities that the Company undertakes in the near future as the securities purchase agreements that the Company entered into on December 10, 2012 and June 17, 2013 with certain investors prohibit the Company from (i) issuing additional equity securities until 60 days after the effective date of a registration statement covering the resale of the common stock issuable upon exercise of the warrants and conversion of the preferred stock sold in those transactions; and (ii) issuing additional debt or equity securities with variable conversion or exercise prices until December 10, 2013 and June 17, 2014, respectively. Management is also actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and strategic partners.  Management has sold its non-essential real estate assets which are classified as Assets Held for Investment to augment its cash position.
	These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. There are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence. The Company’s inability to obtain required funding in the near future or its inability to obtain funding on favorable terms will have a material adverse effect on its operations and strategic development plan for future growth. If the Company cannot successfully raise additional capital and implement its strategic development plan, its liquidity, financial condition and business prospects will be materially and adversely affected, and the Company may have to cease operations.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Jul. 31, 2013
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies:
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. For those consolidated subsidiaries where the Company ownership is less than 100 percent, the outside stockholders’ interests are shown as minority interests. Effective December 17, 2004, the Company’s ownership in all consolidated subsidiaries is 100 percent. All significant intercompany transactions and balances have been eliminated.
	Development Stage Company
	The accompanying consolidated financial statements have been prepared in accordance with the provisions of FASB ASC Topic 915, “Development Stage Entities.”
	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
	Property and Equipment
	Property and equipment are recorded at cost less accumulated depreciation. Depreciation is provided on the straight-line method over the estimated useful lives of the assets, which range from three to thirty years. Gains and losses on depreciable assets retired or sold are recognized in the statement of operations in the year of disposal. Repairs and maintenance expenditures are expensed as incurred.
	Assets Held for Investment
	Property held for investment is recorded at cost less accumulated depreciation. Depreciation is provided on the straight-line method over the estimated useful lives of the assets of thirty years. Gains and losses on depreciable assets retired or sold are recognized in the statement of operations in the year of disposal. Repairs and maintenance expenditures are expensed as incurred.
	Patents
	Capitalized patent costs represent legal costs incurred to establish patents and a portion of the acquisition price paid attributed to patents upon the acquisition of Antigen in August 2003.  When patents reach a mature stage, any associated legal costs are comprised mostly of maintenance fees and costs of national applications and are expensed as incurred.  Capitalized patent costs are amortized on a straight line basis over the remaining life of the patent.  As patents are abandoned, the net book value of the patent is written off. In the fiscal year ended July 31, 2012, the Company recorded a write down of $440,780 on certain patents. There were no write downs or disposals in the fiscal years ended July 31, 2013 or 2011.
	Impairment or Disposal of Long-Lived Assets and Intangibles
	The Company assesses the impairment of long-lived assets under FASB ASC Topic 360 whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable and exceeds its fair value. The carrying amount of the long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset. There were no write downs or disposals in the fiscal year ended July 31, 2013. In the fiscal year ended July 31, 2012, the Company sold, wrote off or disposed of certain long-lived assets with a net book value of $2,945,079. In the fiscal year ended July 31, 2011, the Company recorded a write down of $35,878 on certain equipment.
	Derivative Warrant Liability
	The Company’s derivative warrant instruments are measured at fair value using the binomial valuation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the warrant.  The liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations under the caption “Change in fair value of derivative warrant liability.” See Note 10 – Derivative Liabilities.
	Revenue Recognition and Deferred Revenue
	Revenues from the sale of commercial products are recognized at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. Certain product sales are made to retailers under agreements allowing for a right to return unsold products. In accordance with FASB ASC Topic 605, recognition of revenue on all sales to these retailers is deferred until the right of return expires, the product is sold to a third party or a provision for returns can be reasonably estimated based on historical experience. The cost of inventory under these sales is considered to be consigned inventory until the revenue is recognized. Sales are reported net of estimated returns and allowances, discounts, mail-in rebate redemptions and credit card chargebacks. If actual sales returns, allowances, discounts, mail-in rebate redemptions or credit card chargebacks are greater than estimated by management, additional expense may be incurred. At July 31, 2013, we have $224,843 of deferred revenue for which a provision for returns cannot be reasonably estimated and thus the balance is included in Deferred Revenue on our consolidated balance sheets. The corresponding cost of sales has been previously written off and is not included in inventory as of July 31, 2013 as the timing of the recognition of the revenue cannot be reasonably estimated.
	Grant revenue is recognized as the Company provides the services stipulated in the underlying grant based on the time and expenditures incurred. Amounts received in advance of services provided are recorded as deferred revenue and amortized as revenue when the services are provided. The Company received grant revenue of $488,959 in the fiscal year ended July 31, 2011 and recognized the full amount of the grant in fiscal 2011, as the Company had already incurred all of the qualifying expenses and the amount was fully received. There was no grant revenue in fiscal 2013 or 2012. See Note 13 - Qualifying Therapeutic Discovery Project Program.
	Included in miscellaneous income are fees received under licensing agreements. Nonrefundable fees received under licensing agreements are recognized as revenue when received if the Company has no continuing obligations to the other party.
	Rental income is recognized as revenue in the period in which the related rental space is occupied.
	Research and Development Costs
	Expenditures for research and development are expensed as incurred and include, among other costs, those related to the production of experimental drugs, including payroll costs, and amounts incurred for conducting clinical trials. Amounts expected to be received from governments under research and development tax credit arrangements are offset against current research and development expense.
	Income Taxes
	Income taxes are accounted for under the asset and liability method prescribed by FASB ASC Topic 740. These standards require a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position.  If the more likely than not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. At July 31, 2013 and 2012, the Company had a full valuation allowance equal to the amount of the net deferred tax asset.
	The Company adopted the FASB guidance concerning accounting for uncertainty in income taxes, which clarifies the accounting and disclosure for uncertainty in tax positions, as of August 1, 2007. The guidance requires that the Company determine whether it is more likely than not that a tax position will not be sustained upon examination by the appropriate taxing authority. If a tax position does not meet the more likely than not recognition criterion, the guidance requires that the tax position be measured at the largest amount of benefit greater than 50 percent not likely of being sustained upon ultimate settlement. Based on the Company’s evaluation, management has concluded that there are no significant uncertain tax positions requiring recognition in the consolidated financial statements.
	Stock-Based Compensation
	The Company follows FASB ASC Topic 718 which requires that new, modified and unvested share-based payment transactions with employees, such as grants of stock options and restricted stock, be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the quoted market price or the value of the services provided, whichever is more readily determinable. The Company also follows the guidance in FASB ASC Topic 505 for equity based payments to non-employees for equity instruments issued to consultants and other non-employees.
	Net Loss per Common Share
	Basic earnings per share is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share gives effect to all dilutive potential common shares outstanding during the period. The computation of diluted earnings per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings. Refer to Note 14 for methodology for determining net loss per share.
	Comprehensive Income/(Loss)
	Other comprehensive income/(loss), which includes only foreign currency translation adjustments, is shown in the Statement of Changes in Stockholders’ Equity.
	Concentration of Credit Risk
	The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Canada Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions and has not experienced any collection losses with these financial institutions.
	Foreign Currency Translation
	Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Income statement accounts are translated at a weighted average of exchange rates which were in effect during the period. Translation adjustments that arise from translating the foreign subsidiary’s financial statements from local currency to U.S. currency are recorded in the other comprehensive loss component of stockholders’ equity.
	Fair Value of Financial Instruments
	Fair value is defined under FASB ASC Topic 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for an asset or liability in an orderly transaction between participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The levels are as follows:
		·	Level 1 - Quoted prices in active markets for identical assets or liabilities
		·	Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data for substantially the full term of the assets or liabilities
		·	Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities
	The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, long-term debt, accounts payable and accrued expenses, as well as derivative warrant liabilities and derivative additional investment rights. All of these items, except for the derivative warrant liabilities and derivative additional investment rights, were determined to be Level 1 fair value measurements. The carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate their respective fair values because of the short maturities of these instruments. Long-term debt balances were determined to approximate their fair value as we believe the borrowing rates reflect the prevailing market rates available for similar debt instruments.
	The Company has determined its derivative warrant liability and its derivative additional investment rights liability to be Level 2 fair value measurements and has used the binomial lattice model valuation method to calculate the fair value of the derivative warrant liability and the derivative additional investment rights liability at July 31, 2013, 2012 and 2011. See Note 10 – Derivative Liabilities.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods.
	The Company evaluates its estimates, including those related to bad debts, long lived assets (including patents) impairment valuations, debt obligations, derivatives, convertible preferred shares, long-term contracts, and contingencies and litigation, on an ongoing basis. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
	Critical accounting estimates are reviewed and discussed with the audit committee of the board of directors. The Company considers an accounting estimate to be critical if it requires assumptions to be made that were uncertain at the time the estimate was made, if changes in the estimate if different estimates that could have been selected would have a material impact on our results of operations or financial condition.
	Effects of Recent Accounting Pronouncements
	Recently Adopted Accounting Pronouncements
	In May 2011, the FASB issued further guidance on fair value measurements and disclosures which requires the categorization by level for items that are only required to be disclosed at fair value and information about transfers between Level 1 and Level 2. In addition, the update provides guidance on measuring the fair value of financial instruments managed within a portfolio and the application of premiums and discounts on fair value measurements. The guidance requires additional disclosure for Level 3 measurements regarding the sensitivity of fair value to changes in unobservable inputs and any interrelationships between those inputs. The guidance was effective for the Company’s interim period ended April 30, 2012. The adoption of this new accounting guidance did not have a material impact on the Company’s consolidated financial statements.
	In June 2011, the FASB issued guidance regarding the presentation of Comprehensive Income within financial statements. The guidance was effective for the Company’s annual fiscal period ended July 31, 2013. The adoption of this new accounting guidance did not have a material impact on the Company’s consolidated financial statements.

Longlived_Assets

Long-lived Assets	12 Months Ended
	Jul. 31, 2013
Property, Plant and Equipment [Abstract]
Long-lived Assets	Note 3 - Long-lived Assets:
		Property and Equipment
	The costs and accumulated depreciation of property and equipment are summarized as follows:
		July 31,
		2013		2012
	Land	$	-0-	$	140,450
	Buildings and Improvements		117,898		934,668
	Furniture and Fixtures		23,452		47,794
	Office Equipment		38,690		52,395
	Lab Equipment		327,899		393,781
	Total Property and Equipment		507,939		1,569,088
	Less:  Accumulated Depreciation		422,533		864,410
	Property and Equipment, Net	$	85,406	$	704,678
	Depreciation expense related to property and equipment amounted to $41,890, $97,967 and $172,250 for the years ended July 31, 2013, 2012 and 2011, respectively.
		Assets Held for Investment, Net
	The costs and accumulated depreciation of assets held for investment are summarized as follows:
		July 31,
		2013		2012
	Assets Held For Investment	$	930,726	$	1,179,276
	Less:  Accumulated Depreciation		289,954		320,899
	Assets Held for Investment, Net	$	640,772	$	858,377
	These assets are held as collateral for long term debt (see Note 8). Depreciation expense on assets held for investment amounted to $30,764, $74,070 and $141,686 for the years ended July 31, 2013, 2012 and 2011, respectively.
	The Company’s holds these properties for investment purposes and collects rental income as described directly below.
	Income from Assets Held for Investment, net
	In March 2013, the Company sold a property which was held for investment for gross proceeds after real estate commissions of $256,835. This property had a net book value of $169,566, resulting in an accounting gain of $87,682 which is included in income from assets held for investment, net on the consolidated statement of operations. The property was secured by a mortgage which was partially discharged upon the sale, as described in the last paragraph of this note below. After the partial discharge of the mortgage ($216,810), as well as legal fees, interest, penalties and other costs (approximately $13,000 in aggregate), the sale resulted in net cash proceeds to the Company of $27,025.
	In September 2012, the Company sold its head office real estate in Toronto for gross proceeds after real estate commissions of $1,579,189. This property had a net book value of $585,064, resulting in an accounting gain of $994,125 which is included in income from assets held for investment, net on the consolidated statement of operations. The net proceeds after commissions and other expenses were used to discharge or partially discharge the first and second mortgages on the property. The first mortgage on the property, with remaining principal of $480,951, was discharged completely upon sale. The remaining net proceeds of $1,028,780 after expenses and the discharge of the first mortgages was used to partially discharge the second mortgage and the Company did not receive any of the net proceeds from this property sale.
	In July 2012, the Company sold a property for gross proceeds after real estate commissions of $342,862. This property had a net book value of $107,203, resulting in an accounting gain of $235,659 which is included in income from assets held for investment, net, on the consolidated statement of operations. The net proceeds after commissions and other expenses were used to partially discharge the first and second mortgages on the property and the Company did not receive any of the net proceeds from this property sale.
	In March and April, 2012, the Company sold nine commercial condominium units which were held for investment for gross proceeds after real estate commissions of $2,865,682. These properties had a net book value of $1,783,932, resulting in an accounting gain of $1,081,750 which is included in income from assets held for investment, net on the consolidated statement of operations. The net proceeds after commissions and other expenses were used to discharge or partially discharge the first and second mortgages on the properties. There were two first mortgages on the properties, with combined remaining principals of $571,680, which were discharged completely upon sale. The remaining net proceeds of $2,190,952 after expenses and the discharge of the first mortgages was used to partially discharge the second mortgage and the Company did not receive any of the net proceeds from these property sales.
	In August 2011, the Company sold two properties which were held for investment for gross proceeds after real estate commissions of $1,669,115. These two properties had a net book value of $1,029,435, resulting in an accounting gain of $639,680 which is included in income from assets held for investment, net on the consolidated statement of operations. The two properties had mortgages of $659,288 which were discharged upon sale, resulting in net cash proceeds to the Company of $1,009,827.
	The total accounting gains in this category from property sales in the fiscal years ended July 31, 2013 and 2012 were $1,081,807 and $1,957,089, respectively, compared to zero in the fiscal year ended July 31, 2011.
	The remaining income of $163, 358 and $249,127 in this category in the respective fiscal years ended July 31, 2013 and 2012, pertains to rental income from properties held for investment, net of carrying and operating expenses. In the fiscal year ended July 31, 2011, rental income from properties held for investment, net of operating expenses was $349,458. Gross income from rental operations was $221,399, $384,299 and $582,974 and rental expenses were $58,041, $135,172 and $233,516, including the depreciation expense amounts above relating to assets held for investment, for the years ended July 31, 2013, 2012 and 2011, respectively.
	The properties held for investment have an interest only first mortgage which closed on November 30, 2012 with a principal amount as of July 31, 2013 of $617,665, an interest rate of 9.75% compounded semi-annually and a maturity date of November 30, 2013. This mortgage was completely discharged following the sale of the properties held for investment in August 2013. See Note 18 – Subsequent Events.

Patents

Patents	12 Months Ended
	Jul. 31, 2013
Accounting Policies [Abstract]
Patents	Note 4 - Patents:
	The costs and accumulated amortization of patents are summarized as follows:
		July 31,
		2013		2012
	Patents	$	5,657,455	$	5,587,790
	Less:  Accumulated Amortization		3,338,039		2,953,332
	Patents, Net	$	2,319,416	$	2,634,458
	Weighted Average Life		8.6 years		9.4 years
	Amortization expense amounted to $391,777, $441,087 and $430,650 for the years ended July 31, 2013, 2012 and 2011, respectively. Amortization expense is expected to be approximately $274,000 per year for the years ended July 31, 2014 through 2018. During the year ended July 31, 2013, the Company did not write off any patents. During the year ended July 31, 2012, the Company wrote off patents with a net book value of $440,780 as the patents had been abandoned or were no longer being used. The charge was included in research and development expenses on our consolidated statements of operations. During the year ended July 31, 2011, the Company did not write off any patents.

Income_Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2013
Income Tax Disclosure [Abstract]
Income Taxes	Note 5 - Income Taxes:
	The Company has incurred losses since inception, which have generated net operating loss (“NOL”) carryforwards. The NOL carryforwards arise from both United States and Canadian sources. Pretax losses arising from domestic operations (United States) were $8,025,582, $8,040,033 and $15,060,207 for the years ended July 31, 2013, 2012 and 2011, respectively. Pretax losses arising from foreign operations (Canada) were $528,741, $1,450,244 and $6,615,660 for the years ended July 31, 2013, 2012 and 2011, respectively. As of July 31, 2013, the Company has NOL carryforwards in Generex Biotechnology Corporation of $201,080,721, which expire in 2018 through 2033, in Generex Pharmaceuticals Inc. of approximately $44,924,097, which expire in 2015 through 2033, and in Antigen Express, Inc. of approximately $23,362,008, which expire in 2016 through 2033. These loss carryforwards are subject to limitation due to the acquisition of Antigen and may be limited in future years due to certain structural ownership changes which have occurred over the last several years, related to the Company’s equity and convertible debenture financing transactions.
	For the years ended July 31, 2013, 2012 and 2011, the Company’s effective tax rate differs from the federal statutory rate principally due to net operating losses and other temporary differences for which no benefit was recorded. Additionally, effective for the year ended July 31, 2011, the Company has taken into account a decrease in the Canadian effective tax rate from 36.12% to 26.5% as of January 2012, which will reduce the future value (prior to valuation allowances) of the NOL carryforwards of the Canadian subsidiary.
	Deferred income taxes consist of the following:
		July 31,
		2013			2012
	Net operating loss carryforwards	$	87,541,552		$	85,428,939
	Other temporary differences		800,989			627,656
	Total Deferred Tax Assets		88,342,541			86,056,595
	Valuation Allowance		(88,098,860	)		(85,579,584	)
	Deferred Tax Liabilities
	Intangible assets		(386,320	)		(378,672	)
	Other temporary differences		142,639			(98,339	)
	Total Deferred Tax Liabilities		(243,681	)		(477,011	)
	Net Deferred Income Taxes	$	—		$	—
	A reconciliation of the United States Federal Statutory rate to the Company’s effective tax rate for the years ended July 31, 2013, 2012 and 2011 is as follows:
		2013			2012			2011
	Federal statutory rate		(34.0	)%		(34.0	)%		(34.0	)%
	Increase (decrease) in income taxes resulting from:
	Imputed interest income on intercompany receivables from foreign subsidiaries		6			5			3
	Non-deductible or non-taxable items		13			4			(4.0	)
	Change in Canadian NOL carryforwards due to future tax rate changes		0			0			20
	Other temporary differences		(14.0	)		18			18
	Change in valuation allowance		29			(3.0	)		(3.0	)
	Effective tax rate		—	%		—	%		—	%
	As of July 31, 2013, the Company had no tax benefits which have not been fully allowed for, and no adjustment to its financial position, results of operations or cash flows was required. The Company does not expect that unrecognized tax benefits will increase within the next twelve months. The Company records interest and penalties related to tax matters within other expense on the accompanying consolidated statement of operations. These amounts are not material to the consolidated financial statements for the periods presented. Generally, tax years 2010 to 2013 remain open to examination by the Internal Revenue Agency or other tax jurisdictions to which the Company is subject. The Company’s Canadian tax returns are subject to examination by federal and provincial taxing authorities in Canada. Generally, tax years 2005 to 2013 remain open to examination by the Canadian Customs and Revenue Agency or other tax jurisdictions to which the Company is subject.

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	12 Months Ended
	Jul. 31, 2013
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	Note 6 - Accounts Payable and Accrued Expenses:
	Accounts payable and accrued expenses consist of the following:
		July 31,
		2013		2012
	Accounts Payable & Accruals – General and Administrative	$	3,447,618	$	3,556,160
	Accounts Payable & Accruals – Research and Development		3,557,184		2,691,192
	Accounts Payable & Accruals – Selling and Marketing		328,629		290,534
	Accrued Make Whole Payments on Convertible Preferred Stock (see Note 9)		251,100		402,300
	Executive Compensation and Directors’ Fees Payable		76,703		75,466
	Total	$	7,661,234	$	7,015,652

Commitments_and_Contingent_Lia

Commitments and Contingent Liabilities	12 Months Ended
	Jul. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	Note 7 - Commitments and Contingent Liabilities:
	Leases
	The Company has entered into various operating lease agreements for the use of operating space, vehicles and office equipment.
	Aggregate minimum annual lease commitments of the Company under non-cancelable operating leases as of July 31, 2013 are as follows:
	Fiscal Year	Amount
	2014		152,094
	2015		106,205
	2016 and thereafter		—
	Total Minimum Lease Payments	$	258,299
	Lease expense amounted to approximately $153,000 $185,000 and $210,000for the years ended July 31, 2013, 2012, and 2011, respectively.
	In October 2012, the Company signed a lease for office space in Toronto Canada which runs from October 2012 through September 2014 at a monthly gross rent, including taxes and expenses of approximately $6,800 per month.
	The preceding data reflects existing leases and does not include replacements upon their expiration. In the normal course of business, operating leases are generally renewed or replaced by other leases.
	Supply Agreements and Purchase Obligations
	On December 7, 2009, the Company entered into a long-term agreement with sanofi-aventis Deutschland GmbH (“sanofi”). Under this agreement, sanofi will manufacture and supply recombinant human insulin to the Company in the territories specified in the agreement. Through this agreement, the Company will procure recombinant human insulin crystals for use in the production of Generex Oral-lyn™. The terms of the supply agreement required the Company to make certain minimum purchases of insulin from sanofi through the period ended December 31, 2011. To date, the Company has not met the minimum purchase commitments under this agreement. After December 31, 2011, sanofi may terminate the agreement due to the Company’s failure to meet such purchase commitments. Upon termination, the Company would be obligated to pay sanofi for all materials and components that it has acquired or ordered to manufacture insulin based on the Company’s forecasts or minimum purchase commitments, all related work-in-progress (at cost) and all finished insulin in inventory. To date, the Company has not provided forecasts to sanofi for the purchase of insulin and sanofi has not terminated the agreement.
	The Company has a supply agreement with Presspart Manufacturing Limited (“Presspart”), whereby the Company will purchase its entire requirements for products to use in the administration of insulin through the buccal mucosa and shall not purchase the products or any metal containers competitive to the products from any other person in exchange for an exclusive non-transferable royalty-free irrevocable license to use the products. The contract shall continue for a minimum period of four contract years from the end of the first contract year in which the total quantity of products purchased by the Company from Presspart exceeds 10,000,000 units, and thereafter, shall continue until terminated by either party by giving twelve months written notice. As of July 31, 2013, the Company has not yet completed a contract year in which the total quantity has exceeded 10,000,000 units and as such the expiration date of this contract cannot be determined.
	The Company’s subsidiary, Antigen, has a Clinical Study Agreement with the Henry Jackson Foundation (“HJF”) to provide services related to Antigen’s Phase II AE37 breast cancer trials. The agreement requires quarterly payments to HJF until October 1, 2013. The remaining required payments, after our fiscal year ended July 31, 2013 and until October 1, 2013, total approximately $226,000.
	The Company has a directors and officers insurance policy covering the period from April 28, 2013 to April 28, 2014. We are paying the policy in equal monthly installments until January 28, 2013. As of July 31, 2013, the total remaining installment payments are approximately $108,000.
	Pending Litigation
	In February 2001, a former business associate of the former Vice President of Research and Development (“VP”) of the Company and an entity known as Centrum Technologies Inc. (“CTI”) commenced an action in the Ontario Superior Court of Justice against the Company and the VP seeking, among other things, damages for alleged breaches of contract and tortious acts related to a business relationship between this former associate and the VP that ceased in July 1996. The plaintiffs’ statement of claim also seeks to enjoin the use, if any, by the Company of three patents allegedly owned by CTI. The three patents are entitled Liquid Formulations for Proteinic Pharmaceuticals, Vaccine Delivery System for Immunization, Using Biodegradable Polymer Microspheres, and Controlled Releases of Drugs or Hormones in Biodegradable Polymer Microspheres. It is the Company’s position that the buccal drug delivery technologies which are the subject matter of the Company’s research, development, and commercialization efforts, including Generex Oral-lyn™ and the RapidMist™ Diabetes Management System, do not make use of, are not derivative of, do not infringe upon, and are entirely different from the intellectual property identified in the plaintiffs’ statement of claim. On July 20, 2001, the Company filed a preliminary motion to dismiss the action of CTI as a nonexistent entity or, alternatively, to stay such action on the grounds of want of authority of such entity to commence the action. The plaintiffs brought a cross motion to amend the statement of claim to substitute Centrum Biotechnologies, Inc. (“CBI”) for CTI. CBI is a corporation of which 50 percent of the shares are owned by the former business associate and the remaining 50 percent are owned by the Company. Consequently, the shareholders of CBI are in a deadlock. The court granted the Company’s motion to dismiss the action of CTI and denied the plaintiffs’ cross motion without prejudice to the former business associate to seek leave to bring a derivative action in the name of or on behalf of CBI. The former business associate subsequently filed an application with the Ontario Superior Court of Justice for an order granting him leave to file an action in the name of and on behalf of CBI against the VP and the Company. The Company opposed the application. In September 2003, the Ontario Superior Court of Justice granted the request and issued an order giving the former business associate leave to file an action in the name of and on behalf of CBI against the VP and the Company. A statement of claim was served in July 2004. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.
	On May 20, 2011, Ms. Perri filed a statement of claim (subsequently amended) in the Ontario Superior Court of Justice, naming as defendants the Company and certain directors of the Company, Mr. Barratt, Ms. Masterson, Mr. McGee, and Mr. Fletcher. In this action, Ms. Perri has alleged that defendants engaged in discrimination, harassment, bad faith and infliction of mental distress in connection with the termination of her employment with the Company. Ms. Perri is seeking damages in this action in excess of $7,000,000 for, among other things, breach of contract, breach of fiduciary duty, violations of the Ontario Human Rights Code and aggravated and punitive damages. On September 20, 2011, the defendants filed a statement of defense and counterclaim, also naming Time Release Corp., Khazak Group Consulting Corp., and David Khazak, C.A. as defendants by counterclaim, and seeking damages of approximately $2.3 million in funds that the defendants allege Ms. Perri wrongly caused the Company to pay to third parties in varying amounts over several years and an accounting of certain third-party payments, plus interests and costs. The factual basis for the counterclaim involves payments made by the Company to third parties believed to be related to Ms. Perri. The Company intends to defend this action and pursue its counterclaim vigorously and is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.
	On June 1, 2011, Golden Bull Estates Ltd. filed a claim (subsequently amended) in the Ontario Superior Court of Justice, naming the Company, 1097346 Ontario, Inc. and Generex Pharmaceuticals, Inc. as defendants. The plaintiff, Golden Bull Estates, is controlled by Ms. Perri. The plaintiff alleges damages in the amount of $550,000 for breach of contract, $50,000 for punitive damages, plus interest and costs. The plaintiff’s claims relate to an alleged contract between the plaintiff and the Company for property management services for certain Ontario properties owned by the Company. The Company terminated the plaintiff’s property management services in April 2011. Following the close of pleadings, the Company served a motion for summary judgment. The plaintiff responded by amending its statement of claim to include a claim to the Company’s interest in certain of its real estate holdings. The plaintiff moved for leave to issue and register a Certificate of Pending Litigation in respect of this real estate. The motion was not successful in respect of any current real estate holdings of the Company. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.
	In August 2011, the estate of Antonio Perri, the late father of Ms. Perri, commenced an action against Generex Pharmaceuticals, Inc., the law firm of Brans, Lehun, Baldwin LLP and William Lehun in the Ontario Superior Court of Justice claiming that the estate is entitled to the proceeds of sale (approximately $1,730,000) received by the Company on its sale of two properties to Golden Bull Estates Ltd., a company controlled by Ms. Perri. The suit alleges that no consideration was received when the Company purchased the two properties from Antonio Perri in 1998. The Company has responded to this statement of claim and intends to defend this action vigorously. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.
	In December 2011, a vendor of the Company commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc., in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in addition to costs and further interest.  The Company responded to this statement of claim and also asserted a counterclaim in the proceeding for $200,000 arising from the vendor’s breach of contract and detinue, together with interest and costs. On November 16, 2012, the parties agreed to settle this action and the Company has agreed to pay the plaintiff $125,000, following the spinout of its subsidiary Antigen, from the proceeds of any public or private financing related to Antigen subsequent to such spinout.  Each party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each party’s counsel until payment of the settlement amount.  Following payment to the plaintiff, the parties agree that a Consent Dismissal Order without costs will be filed with the court.  If the Company fails to make the payment following completion of any post-spinout financing related to Antigen or any other subsidiaries, the Plaintiffs may take out a judgment in the amount of the claim plus interest of 3% per annum and costs fixed at $25,000.
	The Company is involved in certain other legal proceedings in addition to those specifically described herein. Subject to the uncertainty inherent in all litigation, the Company does not believe at the present time that the resolution of any of these legal proceedings is likely to have a material adverse effect on the Company’s consolidated financial position, operations or cash flows.
	With respect to all litigation, as additional information concerning the estimates used by the Company becomes known, the Company reassesses its position both with respect to accrued liabilities and other potential exposures.
	Employment Agreements
	As of July 31, 2013, the Company had an employment arrangement with its President & Chief Executive Officer, whereby the Company is required to pay an annual base salary of $475,000. The term of service for this executive extended through March 16, 2008, which term had not been formally extended as of July 31, 2013. In the event the agreement is terminated, by reason other than cause, death, voluntary retirement or disability, the Company is required to pay the employee in one lump sum twelve months base salary and the average annual bonus.
	As of July 31, 2013, the Company has two at will employment agreements with Antigen employees requiring the Company to pay an annual aggregate salary of $371,305 to the two employees. In the event any agreement is terminated by reason other than death, disability, a voluntary termination not for good reason (as defined in the agreement) or a termination for cause, the Company is required to pay the employees severance of six months’ salary, in accordance with the terms of the individual employment agreements.

LongTerm_Debt

Long-Term Debt	12 Months Ended
	Jul. 31, 2013
Debt Disclosure [Abstract]
Long-Term Debt	Note 8 - Long-Term Debt:
	Long-term debt consists of the following:
		July 31,
		2013		2012
	Mortgage payable - interest at 10.0 percent per annum, monthly interest payments of $9,807, principal due January 2013, secured by secondary rights to real property located at 11 Carlaw Avenue and 33 Harbour Square Toronto, Canada	$	-0-	$	1,181,461
	Mortgage payable - interest at 6.75 percent per annum, monthly payments of principal and interest of $6,014, due May 2015, secured by a first mortgage over real property located at 33 Harbour Square, Toronto, Canada		-0-		482,700
	Mortgage payable - interest at 9.75 percent per annum, monthly interest payments of $6,771, principal due November 2013, secured by secondary rights to real property located at 11 Carlaw Avenue, Toronto, Canada		617,665		-0-
	Total Debt		617,665		1,664,161
	Less Current Maturities of Long-Term Debt		617,665		1,222,746
	Total Long-Term Debt	$	-0-	$	441,415
		The first mortgage related to the property at 11 Carlaw was discharged on August 14, 2013, in conjunction with the sale of that property and there is no mortgage debt after that date. See Note 18 – Subsequent Events.
		For the years ended July 31, 2013, 2012 and 2011, the Company incurred $196,101, $568,424 and $205,539, respectively in interest expense on its long-term debt.

Series_A_B_C_D_E_9_Convertible

Series A, B, C, D & E 9% Convertible Preferred Stock	12 Months Ended
	Jul. 31, 2013
Series B C D E 9 Convertible Preferred Stock
Series A, B, C, D & E 9% Convertible Preferred Stock	Note 9 - Series A, B, C, D & E 9% Convertible Preferred Stock :
	Series A 9% Convertible Preferred Stock
	The Company has authorized 5,500 shares of Series A 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated July 8, 2011, the Company sold an aggregate of 2,575 shares of convertible preferred stock, as well as accompanying warrants to purchase 17,166,666 shares of common stocks. An aggregate of 17,166,666 shares of the Company’s common stock were issuable upon conversion of the convertible preferred stock which was issued at the initial closing. As of the end of the Company’s fiscal year 2012, all of the issued Series A 9% Convertible Preferred Stock had been converted to common stock. There were 17,166,666 shares of common stock issued upon the conversion of the Series A convertible preferred stock and 6,129,666 shares of common stock issued as “make-whole payments” on such conversions.
	Series B 9% Convertible Preferred Stock
	The Company has authorized 2,000 shares of Series B 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated January 31, 2012, the Company sold an aggregate of 2,000 shares of Series B convertible preferred stock, as well as accompanying warrants to purchase 13,333,333 shares of common stocks. An aggregate of 13,333,333 shares of the Company’s common stock were issuable upon conversion of the Series B convertible preferred stock which was issued at the initial closing. On December 10, 2012, the triggering of the price protection features of the Series B convertible preferred stock resulted in a decrease of the conversion price from $0.08 to $0.03 per share and a corresponding increase in the number of common shares underlying the remaining 792 shares of Series B convertible preferred stock as of December 10, 2012 from 9,897,500 to 26,393,333. As of the end of the Company’s fiscal quarter ended January 31, 2013, all of the issued Series B 9% Convertible Preferred Stock had been converted to common stock. There were 38,520,832 shares of common stock issued upon the conversion of the Series B convertible preferred stock and 14,819,679 shares of common stock issued as “make-whole payments” on such conversions.
	Accounting for proceeds from the Series B convertible preferred stock financing
	The net cash proceeds from the Series B convertible preferred stock financing were $1,975,000. The proceeds from the financing were allocated first to the warrants that were issued in the financing and second to the make-whole payments. As the assigned fair values were greater than the net cash proceeds from the transaction, the excess was treated as a “deemed dividend” for accounting purposes and was reported on the Company’s consolidated statements of operations for the fiscal year ended July 31, 2012 under the caption “Preferred Stock Dividend”. The calculation methodologies for the fair values of the derivative warrant liability are described in Note 10 – Derivative Liabilities below. The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:
	Accounting allocation of initial proceeds
		Net proceeds		$1,975,000
		Derivative warrant liability fair value		(1,811,746)
		Make-whole payments liability		(540,000)
		Deemed dividend		$(376, 746)
	Series C 9% Convertible Preferred Stock
	The Company has authorized 750 shares of Series C 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated August 8, 2012, the Company sold an aggregate of 750 shares of Series C convertible preferred stock, as well as accompanying warrants to purchase 9,375,000 shares of common stocks. An aggregate of 9,375,000 shares of the Company’s common stock were issuable upon conversion of the Series C convertible preferred stock which was issued at the initial closing. On December 10, 2012, the triggering of the price protection features of the Series C convertible preferred stock resulted in a decrease of the conversion price from $0.08 to $0.03 per share and a corresponding increase in the number of common shares underlying the 650 shares of Series C convertible preferred stock as of December 10, 2012 from 8,125,000 to 21,666,666. As of the end of the Company’s fiscal quarter ended January 31, 2013, all of the issued Series C 9% Convertible Preferred Stock had been converted to common stock. There were 22,916,665 shares of common stock issued upon the conversion of the Series C convertible preferred stock and 6,664,863 shares of common stock issued as “make-whole payments” on such conversions.
	Accounting for proceeds from the Series C convertible preferred stock financing
	The net cash proceeds from the Series C convertible preferred stock financing were $725,000. The proceeds from the financing were allocated first to the warrants that were issued in the financing and second to the make-whole payments. As the assigned fair values were greater than the net cash proceeds from the transaction, the excess was treated as a “deemed dividend” for accounting purposes and was reported on the Company’s interim consolidated statements of operations for the quarter ended October 31, 2012 under the caption “Preferred Stock Dividend”. The calculation methodologies for the fair value of the derivative warrant liability is described in Note 10 – Derivative Liabilities below. The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:
	Accounting allocation of initial proceeds
		Net proceeds		$725,000
		Derivative warrant liability fair value		(624,797)
		Make-whole payments liability		(202,500)
		Deemed dividend		($102,297)
	Series D 9% Convertible Preferred Stock
	The Company has authorized 750 shares of Series D 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated December 10, 2012, the Company sold an aggregate of 750 shares of Series D convertible preferred stock, as well as accompanying warrants to purchase 24,999,999 shares of common stocks. An aggregate of 24,999,999 shares of the Company’s common stock are issuable upon conversion of the Series D convertible preferred stock which was issued at the initial closing. As of July 31, 2013, all of the Series D convertible preferred stock had been converted to common stock. There were 24,999,999 shares of common stock issued upon the conversion of the Series D convertible preferred stock and 7,825,191 shares of common stock issued as “make-whole payments” on such conversions.
	Accounting for proceeds from the Series D convertible preferred stock financing
	The net cash proceeds from the Series D convertible preferred stock financing were $725,000. As the Company did not have sufficient authorized capital for the issuance of the shares underlying the Series D convertible preferred stock at the time of issuance, equity treatment was not permitted under GAAP. The Series D convertible preferred stock was classified as a derivative liability on the Company’s interim consolidated balance sheet as of the previous quarter ended January 31, 2013. Due to the redemption provision in the event that an increase in the Company’s authorized capital was not approved by the stockholders, the Series D convertible preferred stock was reported at that date at its face value of $750,000. Upon the stockholder approval of the increase in authorized capital on March 28, 2013, the Series D convertible preferred stock met the criteria for equity classification and was reclassified as equity at its then face value of $750,000.
			The calculation methodologies for the fair value of the derivative warrant liability is described in Note 10 – Derivative Liabilities below.
			Series E 9% Convertible Preferred Stock
	The Company has authorized 2,450 shares of Series E 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated June 17, 2013, the Company sold an aggregate of 1,225 shares of Series E convertible preferred stock, as well as accompanying warrants to purchase 40,833,335 shares of common stocks. An aggregate of 40,833,335 shares of the Company’s common stock are issuable upon conversion of the Series E convertible preferred stock which was issued at the initial closing.
	Subject to certain ownership limitations, the convertible preferred stock is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of $0.03 per share, and will accrue a 9% dividend until June 17, 2016 and, beginning on June 17, 2016 and on each one year anniversary thereafter, such dividend rate will increase by an additional 3%. The dividend is payable quarterly on September 30, December 31, March 31 and June 30, beginning on June 30, 2013 and on each conversion date in cash, or at the Company’s option, in shares of common stock. In the event that the convertible preferred stock is converted prior to June 17, 2016, the Company will pay the holder of the converted preferred stock an amount equal to $270 per $1,000 of stated value of the convertible preferred stock, less the amount of all prior quarterly dividends paid on such converted preferred stock before the relevant conversion date. Such “make-whole payment” may be made in cash or, at the Company’s option, in shares of its common stock. In addition, beginning June 17, 2016, the Company will pay dividends on shares of preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, and if such dividends are paid. The Company will incur a late fee of 18% per annum on unpaid dividends.
	The conversion price of the convertible preferred stock is subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The conversion price will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then conversion price, except in the event of certain exempt issuances. In addition, the holders of convertible preferred stock will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had converted all of their shares of convertible preferred stock. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the holders of convertible preferred stock will be entitled to receive, upon conversion of their shares, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction.
	The Company may become obligated to redeem the convertible preferred stock in cash upon the occurrence of certain triggering events, including the failure to provide an effective registration statement covering shares of common stock issuable upon conversion of the convertible preferred stock, material breach of certain contractual obligations to the holders of the convertible preferred stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Company’s common stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or regulated quotation services. Upon the occurrence of certain triggering events, each holder of convertible preferred stock will have the option to redeem such holder’s shares of convertible preferred stock for a redemption price payable in shares of common stock or receive an increased dividend rate of 18% on all of such holder’s outstanding convertible preferred stock.
	In conjunction with the issuance of the Series E convertible preferred stock, the Company also issued 40,833,335 warrants to the investors. Subject to certain ownership limitations, the warrants will be exercisable at any time after their date of issuance and on or before the fifth-year anniversary thereafter at an exercise price of $0.03 per share of common stock. The exercise price of the warrants and, in some cases, the number of shares issuable upon exercise, are subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The exercise price and number of shares of common stock issuable upon exercise will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price, except in the event of certain exempt issuances. In addition, the warrant holders will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had exercised all of their warrants. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the warrant holders will be entitled to receive, upon exercise of their warrants, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction. These warrants have been classified as derivative liabilities and are described further in Note 10 – Derivative Liabilities.
	In addition, until the first anniversary of date of the securities purchase agreement, each investor may, in its sole determination, elect to purchase, severally and not jointly with the other investors, in one or more purchases, in the ratio of such investor's original subscription amount to the original aggregate subscription amount of all investors, additional units consisting of convertible preferred stock and warrants at a purchase price of $1,000 per unit with an aggregate subscription amount thereof of up to $1,225,000, which units will have terms identical to the units of convertible preferred stock and warrants issued in connection with the June 2013 closing. These additional investment rights of the investors have been classified as derivative liabilities and are described further in Note 10 – Derivative Liabilities.
	As of July 31, 2013, 295 of the Series E convertible preferred stock had been converted to common stock. There were 9,833,334 shares of common stock issued upon the conversion of the Series E convertible preferred stock and 2,654,999 shares of common stock issued as “make-whole payments” on such conversions.
	Accounting for proceeds from the Series E convertible preferred stock financing
	The net cash proceeds from the Series E convertible preferred stock financing were $1,165,000. The proceeds from the financing were allocated first to the warrants that were issued in the financing, second to the additional investment rights associated with the financing and third to the make whole payments. As the assigned fair values were greater than the net cash proceeds from the transaction, the excess was treated as a “deemed dividend” for accounting purposes and is reported on the Company’s consolidated statement of operations for the year ended July 31, 2013 under the caption “Preferred Stock Dividend”. The calculation methodologies for the fair values of the derivative warrant liability and the derivative additional investment rights liability are described in Note 10 – Derivative Liabilities below. The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:
	Accounting allocation of initial proceeds
		Net proceeds		$1,165,000
		Derivative warrant liability fair value		(1, 189,744)
		Derivative additional investment rights fair value		(1,264,683)
		Make whole payments liability		(330,750)
		Deemed dividend		($1,620,177)
			The initial “make-whole payments” of $330,750 on the Series E convertible preferred stock were accrued as of the date of the financing and the remaining balance of $251,100 (after conversions) are included in Accounts Payable and Accrued Expenses (see Note 6) at July 31, 2013.

Derivative_Liabilities

Derivative Liabilities	12 Months Ended
	Jul. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities:	Note 10 - Derivative Liabilities:
	Derivative warrant liability
	The Company has warrants outstanding with price protection provisions that allow for the reduction in the exercise price of the warrants in the event the Company subsequently issues stock or securities convertible into stock at a price lower than the exercise price of the warrants. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased or decreased proportionately, so that after such adjustment the aggregate exercise price payable for the adjusted number of warrants shall be the same as the aggregate exercise price in effect immediately prior to such adjustment.
	Accounting for Derivative Warrant Liability
	The Company’s derivative warrant instruments have been measured at fair value at July 31, 2013 and 2012 using the binomial lattice model. The Company recognizes all of its warrants with price protection in its consolidated balance sheets as a liability. The liability is revalued at each reporting period and changes in fair value are recognized currently in the consolidated statements of operations. The initial recognition and subsequent changes in fair value of the derivative warrant liability have no effect on the Company’s consolidated cash flows.
	The derivative warrants outstanding at July 31, 2013 are all currently exercisable with a weighted-average remaining life of 3.46 years.
	The revaluation of the warrants at each reporting period, as well as the charges associated with issuing additional warrants due to the price protection features, resulted in the recognition of a loss of $3,148,782 within the Company’s consolidated statements of operations for the fiscal year ended July 31, 2013 and a loss of $1,081,440 for the fiscal year ended July 31, 2012, which is included in the consolidated statements of operations under the caption “Change in fair value of derivative liabilities”. The fair value of the warrants at July 31, 2013 and July 31, 2012 was $5,234,293 and $4,081,627, respectively, which is reported on the consolidated balance sheets under the caption “Derivative Warrant Liability”. The following summarizes the changes in the value of the derivative warrant liability from August 1, 2011 until July 31, 2013:
		Value	No. of Warrants
	Balance at August 1, 2011 – Derivative warrant liability	$   8,745,508	80,234,017
	Exercise of warrants classified as derivative liability	-7,230,734	(49,863,260)
	Additional warrants issued in February 2012 financing	1,811,746	13,333,333
	Additional warrants from price protection features of existing warrants	1,548,813	11,444,440
	Decrease in fair value of derivative warrant liability	(793,706)	n/a
	Balance at July 31, 2012 – Derivative warrant liability	$   4,081,627	55,148,530
	Additional warrants issued in August 2012 financing	624,797	9,375,000
	Additional warrants issued in December 2012 financing	762,355	24,999,999
	Additional warrants issued in June 2013 financing	1,189,744	40,833,335
	Additional warrants from price protection features of existing warrants	7,484,550	236,219,094
	Exercise of warrants	-5,629,130	-145,888,421
	Decrease in fair value of derivative warrant liability	-3,279,650	n/a
	Balance at July 31, 2013 – Derivative warrant liability	$  5,234,293	220,687,537
	Fair Value Assumptions Used in Accounting for Derivative Warrant Liability
	The Company has determined its derivative warrant liability to be a Level 2 fair value measurement and has used the binominal lattice pricing model to calculate the fair value as of July 31, 2013 and July 31, 2012. The binomial lattice model requires six basic data inputs: the exercise or strike price, time to expiration, the risk free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Because the warrants contain the price protection feature, the probability that the exercise price of the warrants would decrease as the stock price decreased was incorporated into the valuation calculations. The key inputs used in the July 31, 2013 and July 31, 2012 fair value calculations were as follows:
			July 31, 2013			July 31, 2012
	Current exercise price		$	0.03		$	0.15
	Time to expiration			3.5 years			3.9 years
	Risk-free interest rate			0.49	%		0.45	%
	Estimated volatility			85	%		104	%
	Dividend			-0-			-0-
	Stock price at period end date		$	0.035		$	0.093
	Fair Value Assumptions Used in Accounting for Derivative Additional Investment Rights Liability
	The Company has determined the derivative additional investment rights liability to be a Level 2 fair value measurement and has used the binominal lattice pricing model to measure the fair value. The fair value of the derivative liability associated with the additional investment rights was determined to be $1,256,160 at July 31, 2013. There were no additional investment rights at July 31, 2012. The key inputs used in the fair value calculation at July 31, 2013 were as follows:
			July 31, 2013
	Underlying number of units of convertible preferred stock			1,225
	Underlying number of warrants			40,833,335
	Current exercise price of warrants		$	0.03
	Current conversion price of preferred stock		$	0.03
	Time to expiration			0.88 years
	Risk-free interest rate			0.11	%
	Estimated volatility			114	%
	Dividend			-0-
	Stock price		$	0.035
	The revaluation of the additional investment rights in the fiscal year ended July 31, 2013, resulted in the recognition of a gain of $8,523 within the Company’s consolidated statements of operations, which is included in the total under the caption “Change in fair value of derivative liabilities”.

Stockholders_DeficiencyEquity

Stockholdersb (Deficiency)/Equity	12 Months Ended
	Jul. 31, 2013
Equity [Abstract]
Stockholdersb (Deficiency)/Equity:	Note 11 - Stockholders’ (Deficiency)/Equity:
	Warrants
	As of July 31, 2013, the Company has the following warrants to purchase common stock outstanding:
	Number of Shares		Warrant Exercise			Warrant
	To be Purchased		Price per Share			Expiration Date
		8,470,661	$	0.76		15-Dec-14
		3,413,928	$	0.79		4-Feb-15
		300,000	$	0.39	(average)	9-Feb-15
		200,000	$	1.25		7-Mar-15
		5,157,813	$	1		15-Mar-15
		102,016,744	$	0.03		March 31, 2016*
		2,508,560	$	0.03		July 11, 2016*
		27,272,720	$	0.03		September 30, 2016*
		7,500,000	$	0.03		February 1, 2017*
		16,389,512	$	0.03		August 10, 2017*
		24,166,666	$	0.03		December 12, 2017*
		40,833,335	$	0.03		June 17, 2018*
		238,229,939
	* Subject to price protection provisions as described below.
	The outstanding warrants at July 31, 2013 have a weighted average exercise price of $0.089 per share and have a weighted average remaining life of 3.31 years.
	As of July 31, 2013, the Company has 102,016,744 warrants with a current exercise price of $0.03 and an expiry date of March 31, 2016, 2,508,560 warrants with a current exercise price of $0.03 and an expiry date of July 11, 2016, 27,272,720 warrants with a current exercise price of $0.03 and an expiry date of September 30, 2016, 7,500,000 warrants with a current exercise price of $0.03 and an expiry date of February 1, 2017, 16,389,512 warrants with a current exercise price of $0.03 and an expiry date of August 10, 2017, 24,166,666 warrants with a current exercise price of $0.03 and an expiry date of December 12, 2017 and 40,833,335 warrants with a current exercise price of $0.03 and an expiry date of June 17, 2018 (220,687,537 warrants in total), which have price protection provisions that allow for the reduction in the current exercise price upon the occurrence of certain events, including the Company’s issuance of common stock or securities convertible into or exercisable for common stock, such as options and warrants, at a price per share less than the exercise price then in effect. For instance, if the Company issues shares of its common stock or options exercisable for or securities convertible into common stock at an effective price per share of common stock less than the exercise price then in effect, the exercise price will be reduced to the effective price of the new issuance. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased proportionately, so that after such adjustment the aggregate exercise price payable for the adjusted number of warrants shall be the same as the aggregate exercise price in effect immediately prior to such adjustment.
	The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants described above that were issued in connection with the March 2008 private placement: (a) shares of common stock or standard options to the Company’s directors, officers, employees or consultants pursuant to a board-approved equity compensation program or other contract or arrangement (up to an aggregate amount of 5,608,926, representing 5% of the common stock issued and outstanding immediately prior to March 31, 2008); (b) shares of common stock issued upon the conversion or exercise of any security, right or other instrument convertible or exchangeable into common stock (or securities exchangeable into common stock) issued prior to March 31, 2008; (c) the shares of common stock issued upon exercise of the warrants issued in March 2008; and (d) shares of common stock and warrants in connection with strategic alliances, acquisitions, mergers, and strategic partnerships, the primary purpose of which is not to raise capital, and which are approved in good faith by the Company’s board of directors (up to an aggregate number of 11,217,852, representing 10% of the shares of common stock issued and outstanding immediately prior to March 31, 2008).
	The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on July 8, 2011: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated July 8, 2011, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreement dated July 8, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on July 8, 2011, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.
	The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on February 2, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011 and January 31, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on February 2, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.
	The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on August 10, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated August 8, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011, January 31, 2012 and August 8, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on August 8, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.
	The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on December 10, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated December 10, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011, January 31, 2012, August 8, 2012 and December 10, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on December 10, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.
	The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on June 17, 2013: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated June 17, 2013, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011, January 31, 2012, August 8, 2012, December 10, 2012 and June 17, 2013 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on June 17, 2013, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.
	The Company accounts for the warrants with price protection provisions in accordance with FASB ASC Topic 815 as described in Note 10 - Derivative Liabilities below. As of July 31, 2013, there were a total of 220,687,537 warrants with an estimated fair value of $5,234,293, which are identified on the consolidated balance sheets under the caption “Derivative Warrant Liability”.
	Preferred Stock
	The Company has authorized 1,000,000 shares of preferred stock with a par value of one-tenth of a cent ($.001) per share. The preferred stock may be issued in various series and shall have preference as to dividends and to liquidation of the Company. The Company’s Board of Directors is authorized to establish the specific rights, preferences, voting privileges and restrictions of such preferred stock, or any series thereof. At July 31, 2013, 930 shares of the Company’s non-voting Series E 9% Convertible Preferred Stock were issued and outstanding. At July 31, 2012, 1,490 shares of the Company’s non-voting Series B 9% Convertible Preferred Stock were issued and outstanding. See Note 9 - Series A, B, C, D and E 9% Convertible Preferred Stock above.
	Equity Instruments Issued for Services Rendered
	During the years ended July 31, 2013, 2012 and 2011, the Company issued stock options, warrants and shares of common stock in exchange for services rendered to the Company. The fair value of each stock option and warrant was valued using the Black Scholes pricing model which takes into account as of the grant date the exercise price and expected life of the stock option or warrant, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk free interest rate for the term of the stock option or warrant. Shares of common stock are valued at the quoted market price on the date of grant. The fair value of each grant was charged to the related expense in the consolidated statement of operations for the services received.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Jul. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation:	Note 12 – Stock-Based Compensation:
	Stock Option Plans
	As of July 31, 2013, the Company had two stockholder-approved stock incentive plans under which shares and options exercisable for shares of common stock have been or may be granted to employees, directors, consultants and advisors. A total of 12,000,000 shares of common stock are reserved for issuance under the 2001 Stock Option Plan (the 2001 Plan) and 60,000,000 shares of common stock are reserved for issuance under the 2006 Stock Plan as amended (the 2006 Plan). At July 31, 2013, there were 4,650,222 and 7,113,391 shares of common stock reserved for future awards under the 2001 Plan and 2006 Plan, respectively. The Company issues new shares of common stock from the shares reserved under the respective Plans upon conversion or exercise of options and issuance of restricted shares.
	The 2001 and 2006 Plans (the Plans) are administered by the Board of Directors (the Board). The Board is authorized to select from among eligible employees, directors, advisors and consultants those individuals to whom options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe, amend and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision of the Plans or any options granted hereunder is within the discretion of the Board.
	The Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors and consultants are eligible to receive options which are not ISOs, i.e. “Non-Qualified Options.” The options granted by the Board in connection with its adoption of the Plans were Non-Qualified Options. In addition, the 2006 Plan also provides for restricted stock grants.
		Share-based employee compensation related to stock options for the years ended July 31, 2013, 2012 and 2011 amounted to $837,753, $602,384 and $936,465 for each year and were charged to the consolidated statements of operations.  Share-based employee compensation related to common stock grants for the years ended July 31, 2013, 2012 and 2011 amounted to 0, $130,544 and $100,999, respectively, and were charged to the consolidated statements of operations.
	The fair value of each option granted is estimated on grant date using the Black-Scholes option pricing model which takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option. The Black-Scholes option pricing model was not used to estimate the fair value any option grants in the fiscal years ended July 31, 2013 and 2012. The following are the variables used to calculate the fair value for the options granted in the fiscal year ended July 31, 2011:
		Risk-Free			Expected		Expected			Expected
		Interest Rate			Life (Years)		Volatility			Dividends
	31-Jul-11		0.13	%		5		101	%		-0-
	The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:
					Weighted Average
					Exercise Price
		Options			per Share
	Outstanding - August 1, 2010		7,465,638		$	0.49
	Granted		3,300,000		$	0.28
	Forfeited or expired		(2,848,704	)	$	0.41
	Exercised		(576,752	)	$	0.001
	Outstanding - July 31, 2011		7,340,182		$	0.46
	Granted		5,851,696		$	0.001
	Forfeited or expired		(912,250	)	$	0.65
	Exercised		(1,299,994	)	$	0.001
	Outstanding - July 31, 2012		10,979,634		$	0.26
	Granted		24,532,719		$	0.001
	Forfeited or expired		(630,778	)	$	0.75
	Exercised		(5,180,378	)	$	0.001
	Outstanding - July 31, 2013		29,701,197		$	0.08
	Exercisable - July 31, 2013		29,641,197		$	0.08
	The 29,701,197 outstanding options at July 31, 2013 had a weighted average remaining contractual term of 4.21 years.
	Options typically vest over a period of two to four years and have a contractual life of five to ten years.
	The following is a summary of the non-vested common stock options granted, vested and forfeited under the Plan:
					Weighted Average
					Grant Date
		Options			Fair Value
	Outstanding - August 1, 2012		172,500		$	0.46
	Granted		24,532,719		$	0.001
	Vested		(24,618,969	)	$	0.016
	Forfeited		(26,250	)	$	0.46
	Outstanding - July 31, 2013		60,000		$	0.46
	As of July 31, 2013, the Company had $5,365 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 0.2 years.
	During the twelve months ended July 31, 2013, the Company granted 24,532,719 options to executives, employees and directors in full and final payment of obligations to pay such individuals deferred salary or director fees. The options were issued in lieu of cash payment of deferred compensation amounts due to such individuals. The number of options granted to each individual was equal to the dollar amount of deferred salary or fees due to such individual divided by the closing price of the Company's common stock on February 5, 2013 ($0.038), March 5, 2013 ($0.034) and June 4, 2013 ($0.0325). The stock options had an exercise price equal to $0.001 per share and were made pursuant to the terms of the Company's 2006 Stock Plan. The options were fully vested at the dates of the grants and expire on the fifth anniversary of the respective dates of grant. The grants were valued at the amount of deferred compensation owed to each such individual.
	During the twelve months ended July 31, 2012, the Company granted 5,851,696 options to executives, employees and directors in full and final payment of obligations to pay such individuals deferred salary or director fees. The options were issued in lieu of cash payment of deferred compensation amounts due to such individuals. The number of options granted to each individual was equal to the dollar amount of deferred salary or fees due to such individual divided by the closing price of the Company's common stock on June 6, 2012 ($0.0925). The stock options had an exercise price equal to $0.001 per share and were made pursuant to the terms of the Company's 2006 Stock Plan. The options were fully vested at the date of grant and expire on the fifth anniversary of the date of grant. The grants were valued at the amount of deferred compensation owed to each such individual.
	During the twelve months ended July 31, 2011, the Company granted 3,300,000 options to executives, directors and management employees, as compensation. The total fair value of the options at the date of grant was $692,010. The options vested immediately and a charge of $692,010 was recorded at the date of grant. The fair value of each option granted was estimated on the grant date using the Black-Scholes option pricing model, taking into account the grant date exercise price and current price of the underlying stock of $0.282, an expected life of the option of 5 years, an expected volatility of 101.3%, expected dividends on the stock of $0 and the risk-free interest rate for the term of the option of 0.13%.
	The following table summarizes information on stock options outstanding at July 31, 2013:
		Options Outstanding
							Weighted
		Number			Weighted		Average
		Outstanding			Average		Remaining			Aggregate
	Range of	at			Exercise		Life			Intrinsic
	Exercise Price	July 31, 2013			Price		(Years)			Value
	$0.00		24,446,197		$	0.001		4.49
	$0.19 - $0.38		3,150,000		$	0.28		2.6
	$0.39 - $0.58		200,000		$	0.56		1.24
	$0.59 - $0.77		1,485,000		$	0.63		4.31
	$0.78 - $0.96		420,000		$	0.94		1.24
			29,701,197		$	0.08		4.21		$	812,259
		Options Exercisable
							Weighted
		Number			Weighted		Average
		Outstanding			Average		Remaining			Aggregate
	Range of	at			Exercise		Life			Intrinsic
	Exercise Price	July 31, 2013			Price		(Years)			Value
	$0.001 - $0.18		24,446,197		$	0.001		4.49
	$0.19 - $0.38		3,150,000		$	0.28		2.6
$0.39 - $0.58		200,000		$	0.56		1.24
$0.59 - $0.77		1,425,000		$	0.63		4.44
$0.78 - $0.96		420,000		$	0.94		1.24
		29,641,197		$	0.08		4.22		$	812,259
	For the Year Ended July 31,
	2013			2012		2011
Weighted Average Grant Date Fair Value of Options Granted	$	0.033		$	0.09	$	0.21
Aggregate Intrinsic Value of Options Exercised	$	178,040		$	119,214	$	166,681
Cash Received for Exercise of Stock Options	$	5,180		$	1,299	$	577
The intrinsic value is calculated as the difference between the market value as of July 31, 2013, 2012 and 2011 and the exercise price of the shares on the respective dates. The market values as of July 31, 2013, 2012 and 2011 were $0.035, $0.093 and $0.13, respectively, based on the high and low bid information for July 31, 2013, 2012 and 2011.

Qualifying_Therapeutic_Discove

Qualifying Therapeutic Discovery Project Program	12 Months Ended
	Jul. 31, 2013
Notes to Financial Statements
Qualifying Therapeutic Discovery Project Program	Note 13 - Qualifying Therapeutic Discovery Project Program:
	In the Company’s fiscal year ended July 31, 2011, the Company’s wholly-owned subsidiary Antigen Express, Inc. received notification that it had been awarded a total cash grant of $488,959 under the Qualifying Therapeutic Discovery Project program administered under Section 48D of the Internal Revenue Code, all of which relates to qualifying expenses that had previously been incurred. The Company recognized the full amount of the grant in the fiscal year ended July 31, 2011, as the Company has already incurred all of the qualifying expenses and the amount has been fully received. Since this program is non-recurring in nature, the Company elected to classify this payment as other income in the consolidated statements of operations for the fiscal year ended July 31, 2011 and it is reported in the “Miscellaneous Income” line item.

Net_Loss_per_Share

Net Loss per Share	12 Months Ended
	Jul. 31, 2013
Earnings Per Share [Abstract]
Net Loss per Share	Note 14 - Net Loss per Share:
	Basic loss per share (“EPS”) and Diluted EPS for the years ended July 31, 2013, 2012 and 2011 have been computed by dividing the net loss available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants, non-vested restricted stock and shares to be issued upon conversion of the outstanding convertible preferred stock, representing approximately 298,931,138, 94,643,712 and 115,875,372 incremental shares, have been excluded from the respective 2013, 2012 and 2011 computation of diluted EPS as they are anti-dilutive due to the losses generated during the respective years.

Supplemental_Disclosure_of_Cas

Supplemental Disclosure of Cash Flow Information	12 Months Ended
	Jul. 31, 2013
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	Note 15 - Supplemental Disclosure of Cash Flow Information:
		For the Years Ended July 31,
		2013		2012		2011
	Cash paid during the year for:
	Interest	$	327,722	$	592,525	$	208,906
	Income taxes	$	—	$	—	$	—
	Disclosure of non-cash investing and financing activities:
	Year Ended July 31, 2013
	Issuance of common stock as payment of dividends on preferred stock	$	886,950
	Year Ended July 31, 2012
	Issuance of common stock as payment of dividends on preferred stock	$	485,190
	Year Ended July 31, 2011
	Issuance of common stock as payment of dividends on preferred stock	$	347,760
	Issuance of common stock as satisfaction of accounts payable and accrued expenses	$	1,110,867

Segment_Information

Segment Information	12 Months Ended
	Jul. 31, 2013
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 16 - Segment Information:
	The Company follows FASB ASC Topic 815 which establishes standards for the way that public business enterprises report information about operating segments in annual financial statements and requires that those enterprises report selected information about operating segments in interim financial reports. This Topic also establishes standards for related disclosures about products and services, geographic areas, and major customers.
	This Topic uses a management approach for determining segments. The management approach designates the internal organization that is used by management for making operating decisions and assessing performance as the source of the Company’s reportable segments. The Company’s management reporting structure provides for only one segment: the research, development and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
	The regions and countries in which the Company had identifiable assets and revenues are presented in the following table. Identifiable assets are those that can be directly associated with a geographic area.
		2013		2012
	Identifiable Assets
	Canada	$	2,825,894	$	2,350,818
	United States		2,026,969		2,293,556
	Middle East, North Africa (MENA)		—		—
	Total	$	4,852,863	$	4,644,374
		2013		2012		2011
	Revenue
	Canada	$	—	$	23,067	$	61,111
	United States		—		5,584		60,867
	Middle East, North Africa (MENA)		—		—		169,650
	Total	$	—	$	28,651	$	291,628

Quarterly_Information_Unaudite

Quarterly Information (Unaudited)	12 Months Ended
	Jul. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Quarterly Information (Unaudited)	Note 17 – Quarterly Information (Unaudited):
	The following schedule sets forth certain unaudited financial data for the preceding eight quarters ending July 31, 2013. In our opinion, the unaudited information set forth below has been prepared on the same basis as the audited information and includes all adjustments necessary to present fairly the information set forth herein. The operating results for the quarter are not indicative of results for any future period.
		Q1	Q2	Q3	Q4
	Fiscal Year July 31, 2013:
	Revenues, net	$               -0-	$               -0-	$               -0-	$               -0-
	Operating Loss	$ (1,940,031)	$ (1,290,780)	$ (1,433,640)	$ (1,464,908)
	Net Income/(Loss)	$   (656,199)	$ (5,640,985)	$  1,297,448	$ (3,554,586)
	Net Loss available to common stockholders	$   (758,496)	$ (5,640,985)	$  1,297,448	$ (5,174,763)
	Net Loss per share	$          0.002	$       (0.015)	$          0.003	$       (0.007)
	Fiscal Year July 31, 2012:
	Revenues, net	$         9,931	$          4,958	$          7,012	$      6,750
	Operating Loss	$ (3,469,778)	$ (1,786,231)	$ (2,466,270)	$ (2,301,769)
	Net Income/(Loss)	$      336,354	$ (9,118,651)	$      867,857	$ (1,575,838)
	Net Loss available to common stockholders	$      336,354	$ (9,118,651)	$      491,111	$ (1,575,838)
	Net Loss per share	$          0.001	$       (0.028)	$          0.003	$       (0.005)

Subsequent_Events

Subsequent Events	12 Months Ended
	Jul. 31, 2013
Subsequent Events [Abstract]
Subsequent Events	Note 18 - Subsequent Events:
	On August 14, 2013, the Company sold its commercial property at 11 Carlaw Avenue for gross proceeds of approximately $926,000. This property had a net book value of $699,248 and the resulting gain on sale of this property will be recognized in the first quarter of fiscal 2014. The net cash proceeds after real estate commissions and other fees were used to pay down the mortgage on this property and the Company received net proceeds of approximately $209,000 from the sale of this property after mortgage repayments and fees.
	The Company has evaluated subsequent events occurring after the balance sheet date through the date the consolidated financial statements were issued.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2013
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. For those consolidated subsidiaries where the Company ownership is less than 100 percent, the outside stockholders’ interests are shown as minority interests. Effective December 17, 2004, the Company’s ownership in all consolidated subsidiaries is 100 percent. All significant intercompany transactions and balances have been eliminated.
Development Stage Company	Development Stage Company
	The accompanying consolidated financial statements have been prepared in accordance with the provisions of FASB ASC Topic 915, “Development Stage Entities.”
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Property and Equipment	Property and Equipment
	Property and equipment are recorded at cost less accumulated depreciation. Depreciation is provided on the straight-line method over the estimated useful lives of the assets, which range from three to thirty years. Gains and losses on depreciable assets retired or sold are recognized in the statement of operations in the year of disposal. Repairs and maintenance expenditures are expensed as incurred.
Assets Held for Investment	Assets Held for Investment
	Property held for investment is recorded at cost less accumulated depreciation. Depreciation is provided on the straight-line method over the estimated useful lives of the assets of thirty years. Gains and losses on depreciable assets retired or sold are recognized in the statement of operations in the year of disposal. Repairs and maintenance expenditures are expensed as incurred.
Patents	Patents
	Capitalized patent costs represent legal costs incurred to establish patents and a portion of the acquisition price paid attributed to patents upon the acquisition of Antigen in August 2003.  When patents reach a mature stage, any associated legal costs are comprised mostly of maintenance fees and costs of national applications and are expensed as incurred.  Capitalized patent costs are amortized on a straight line basis over the remaining life of the patent.  As patents are abandoned, the net book value of the patent is written off. In the fiscal year ended July 31, 2012, the Company recorded a write down of $440,780 on certain patents. There were no write downs or disposals in the fiscal years ended July 31, 2013 or 2011.
Impairment or Disposal of Long-Lived Assets and Intangibles	Impairment or Disposal of Long-Lived Assets and Intangibles
	The Company assesses the impairment of long-lived assets under FASB ASC Topic 360 whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable and exceeds its fair value. The carrying amount of the long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset. There were no write downs or disposals in the fiscal year ended July 31, 2013. In the fiscal year ended July 31, 2012, the Company sold, wrote off or disposed of certain long-lived assets with a net book value of $2,945,079. In the fiscal year ended July 31, 2011, the Company recorded a write down of $35,878 on certain equipment.
Derivative Warrant Liability	Derivative Warrant Liability
	The Company’s derivative warrant instruments are measured at fair value using the binomial valuation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the warrant.  The liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations under the caption “Change in fair value of derivative warrant liability.” See Note 10 – Derivative Liabilities.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue
	Revenues from the sale of commercial products are recognized at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. Certain product sales are made to retailers under agreements allowing for a right to return unsold products. In accordance with FASB ASC Topic 605, recognition of revenue on all sales to these retailers is deferred until the right of return expires, the product is sold to a third party or a provision for returns can be reasonably estimated based on historical experience. The cost of inventory under these sales is considered to be consigned inventory until the revenue is recognized. Sales are reported net of estimated returns and allowances, discounts, mail-in rebate redemptions and credit card chargebacks. If actual sales returns, allowances, discounts, mail-in rebate redemptions or credit card chargebacks are greater than estimated by management, additional expense may be incurred. At July 31, 2013, we have $224,843 of deferred revenue for which a provision for returns cannot be reasonably estimated and thus the balance is included in Deferred Revenue on our consolidated balance sheets. The corresponding cost of sales has been previously written off and is not included in inventory as of July 31, 2013 as the timing of the recognition of the revenue cannot be reasonably estimated.
	Grant revenue is recognized as the Company provides the services stipulated in the underlying grant based on the time and expenditures incurred. Amounts received in advance of services provided are recorded as deferred revenue and amortized as revenue when the services are provided. The Company received grant revenue of $488,959 in the fiscal year ended July 31, 2011 and recognized the full amount of the grant in fiscal 2011, as the Company had already incurred all of the qualifying expenses and the amount was fully received. There was no grant revenue in fiscal 2013 or 2012. See Note 13 - Qualifying Therapeutic Discovery Project Program.
	Included in miscellaneous income are fees received under licensing agreements. Nonrefundable fees received under licensing agreements are recognized as revenue when received if the Company has no continuing obligations to the other party.
	Rental income is recognized as revenue in the period in which the related rental space is occupied.
Research and Development Costs	Research and Development Costs
	Expenditures for research and development are expensed as incurred and include, among other costs, those related to the production of experimental drugs, including payroll costs, and amounts incurred for conducting clinical trials. Amounts expected to be received from governments under research and development tax credit arrangements are offset against current research and development expense.
Income Taxes	Income Taxes
	Income taxes are accounted for under the asset and liability method prescribed by FASB ASC Topic 740. These standards require a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position.  If the more likely than not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. At July 31, 2013 and 2012, the Company had a full valuation allowance equal to the amount of the net deferred tax asset.
	The Company adopted the FASB guidance concerning accounting for uncertainty in income taxes, which clarifies the accounting and disclosure for uncertainty in tax positions, as of August 1, 2007. The guidance requires that the Company determine whether it is more likely than not that a tax position will not be sustained upon examination by the appropriate taxing authority. If a tax position does not meet the more likely than not recognition criterion, the guidance requires that the tax position be measured at the largest amount of benefit greater than 50 percent not likely of being sustained upon ultimate settlement. Based on the Company’s evaluation, management has concluded that there are no significant uncertain tax positions requiring recognition in the consolidated financial statements.
Stock-Based Compensation	Stock-Based Compensation
	The Company follows FASB ASC Topic 718 which requires that new, modified and unvested share-based payment transactions with employees, such as grants of stock options and restricted stock, be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the quoted market price or the value of the services provided, whichever is more readily determinable. The Company also follows the guidance in FASB ASC Topic 505 for equity based payments to non-employees for equity instruments issued to consultants and other non-employees.
Net Loss per Common Share	Net Loss per Common Share
	Basic earnings per share is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share gives effect to all dilutive potential common shares outstanding during the period. The computation of diluted earnings per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings. Refer to Note 14 for methodology for determining net loss per share.
Comprehensive Income/(Loss)	Comprehensive Income/(Loss)
	Other comprehensive income/(loss), which includes only foreign currency translation adjustments, is shown in the Statement of Changes in Stockholders’ Equity.
Concentration of Credit Risk	Concentration of Credit Risk
	The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Canada Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions and has not experienced any collection losses with these financial institutions.
Foreign Currency Translation	Foreign Currency Translation
	Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Income statement accounts are translated at a weighted average of exchange rates which were in effect during the period. Translation adjustments that arise from translating the foreign subsidiary’s financial statements from local currency to U.S. currency are recorded in the other comprehensive loss component of stockholders’ equity.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	Fair value is defined under FASB ASC Topic 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for an asset or liability in an orderly transaction between participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The levels are as follows:
		·	Level 1 - Quoted prices in active markets for identical assets or liabilities
		·	Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data for substantially the full term of the assets or liabilities
		·	Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities
	The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, long-term debt, accounts payable and accrued expenses, as well as derivative warrant liabilities and derivative additional investment rights. All of these items, except for the derivative warrant liabilities and derivative additional investment rights, were determined to be Level 1 fair value measurements. The carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate their respective fair values because of the short maturities of these instruments. Long-term debt balances were determined to approximate their fair value as we believe the borrowing rates reflect the prevailing market rates available for similar debt instruments.
	The Company has determined its derivative warrant liability and its derivative additional investment rights liability to be Level 2 fair value measurements and has used the binomial lattice model valuation method to calculate the fair value of the derivative warrant liability and the derivative additional investment rights liability at July 31, 2013, 2012 and 2011. See Note 10 – Derivative Liabilities.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods.
	The Company evaluates its estimates, including those related to bad debts, long lived assets (including patents) impairment valuations, debt obligations, derivatives, convertible preferred shares, long-term contracts, and contingencies and litigation, on an ongoing basis. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
	Critical accounting estimates are reviewed and discussed with the audit committee of the board of directors. The Company considers an accounting estimate to be critical if it requires assumptions to be made that were uncertain at the time the estimate was made, if changes in the estimate if different estimates that could have been selected would have a material impact on our results of operations or financial condition.
Effects of Recent Accounting Pronouncements	Effects of Recent Accounting Pronouncements
	Recently Adopted Accounting Pronouncements
	In May 2011, the FASB issued further guidance on fair value measurements and disclosures which requires the categorization by level for items that are only required to be disclosed at fair value and information about transfers between Level 1 and Level 2. In addition, the update provides guidance on measuring the fair value of financial instruments managed within a portfolio and the application of premiums and discounts on fair value measurements. The guidance requires additional disclosure for Level 3 measurements regarding the sensitivity of fair value to changes in unobservable inputs and any interrelationships between those inputs. The guidance was effective for the Company’s interim period ended April 30, 2012. The adoption of this new accounting guidance did not have a material impact on the Company’s consolidated financial statements.
	In June 2011, the FASB issued guidance regarding the presentation of Comprehensive Income within financial statements. The guidance was effective for the Company’s annual fiscal period ended July 31, 2013. The adoption of this new accounting guidance did not have a material impact on the Company’s consolidated financial statements.

Longlived_Assets_Tables

Long-lived Assets (Tables)	12 Months Ended
	Jul. 31, 2013
Property, Plant and Equipment [Abstract]
Property and Equipment	The costs and accumulated depreciation of property and equipment are summarized as follows:
		July 31,
		2013		2012
	Land	$	-0-	$	140,450
	Buildings and Improvements		117,898		934,668
	Furniture and Fixtures		23,452		47,794
	Office Equipment		38,690		52,395
	Lab Equipment		327,899		393,781
	Total Property and Equipment		507,939		1,569,088
	Less:  Accumulated Depreciation		422,533		864,410
	Property and Equipment, Net	$	85,406	$	704,678
Assets Held for Investment, Net	The costs and accumulated depreciation of assets held for investment are summarized as follows:
		July 31,
		2013		2012
	Assets Held For Investment	$	930,726	$	1,179,276
	Less:  Accumulated Depreciation		289,954		320,899
	Assets Held for Investment, Net	$	640,772	$	858,377

Patents_Tables

Patents (Tables)	12 Months Ended
	Jul. 31, 2013
Accounting Policies [Abstract]
Costs and accumulated amortization of patents		July 31,
		2013		2012
	Patents	$	5,657,455	$	5,587,790
	Less:  Accumulated Amortization		3,338,039		2,953,332
	Patents, Net	$	2,319,416	$	2,634,458
	Weighted Average Life		8.6 years		9.4 years

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2013
Income Tax Disclosure [Abstract]
Deferred income taxes	Deferred income taxes consist of the following:
		July 31,
		2013			2012
	Net operating loss carryforwards	$	87,541,552		$	85,428,939
	Other temporary differences		800,989			627,656
	Total Deferred Tax Assets		88,342,541			86,056,595
	Valuation Allowance		(88,098,860	)		(85,579,584	)
	Deferred Tax Liabilities
	Intangible assets		(386,320	)		(378,672	)
	Other temporary differences		142,639			(98,339	)
	Total Deferred Tax Liabilities		(243,681	)		(477,011	)
	Net Deferred Income Taxes	$	—		$	—
Reconciliation of effective tax rate	A reconciliation of the United States Federal Statutory rate to the Company’s effective tax rate for the years ended July 31, 2013, 2012 and 2011 is as follows:
		2013			2012			2011
	Federal statutory rate		(34.0	)%		(34.0	)%		(34.0	)%
	Increase (decrease) in income taxes resulting from:
	Imputed interest income on intercompany receivables from foreign subsidiaries		6			5			3
	Non-deductible or non-taxable items		13			4			(4.0	)
	Change in Canadian NOL carryforwards due to future tax rate changes		0			0			20
	Other temporary differences		(14.0	)		18			18
	Change in valuation allowance		29			(3.0	)		(3.0	)
	Effective tax rate		—	%		—	%		—	%

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses - Accounts payable and accrued expenses (Tables)	12 Months Ended
	Jul. 31, 2013
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	Accounts payable and accrued expenses consist of the following:
		July 31,
		2013		2012
	Accounts Payable & Accruals – General and Administrative	$	3,447,618	$	3,556,160
	Accounts Payable & Accruals – Research and Development		3,557,184		2,691,192
	Accounts Payable & Accruals – Selling and Marketing		328,629		290,534
	Accrued Make Whole Payments on Convertible Preferred Stock (see Note 9)		251,100		402,300
	Executive Compensation and Directors’ Fees Payable		76,703		75,466
	Total	$	7,661,234	$	7,015,652

Commitments_and_Contingent_Lia1

Commitments and Contingent Liabilities - (Tables)	12 Months Ended
	Jul. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Aggregate minimum commitments under non-cancelable operating leases	Aggregate minimum annual lease commitments of the Company under non-cancelable operating leases as of July 31, 2013 are as follows:
	Fiscal Year	Amount
	2014		152,094
	2015		106,205
	2016 and thereafter		—
	Total Minimum Lease Payments	$	258,299

LongTerm_Debt_Tables

Long-Term Debt (Tables)	12 Months Ended
	Jul. 31, 2013
Debt Disclosure [Abstract]
Long-term debt	Long-term debt consists of the following:
		July 31,
		2013		2012
	Mortgage payable - interest at 10.0 percent per annum, monthly interest payments of $9,807, principal due January 2013, secured by secondary rights to real property located at 11 Carlaw Avenue and 33 Harbour Square Toronto, Canada	$	-0-	$	1,181,461
	Mortgage payable - interest at 6.75 percent per annum, monthly payments of principal and interest of $6,014, due May 2015, secured by a first mortgage over real property located at 33 Harbour Square, Toronto, Canada		-0-		482,700
	Mortgage payable - interest at 9.75 percent per annum, monthly interest payments of $6,771, principal due November 2013, secured by secondary rights to real property located at 11 Carlaw Avenue, Toronto, Canada		617,665		-0-
	Total Debt		617,665		1,664,161
	Less Current Maturities of Long-Term Debt		617,665		1,222,746
	Total Long-Term Debt	$	-0-	$	441,415

Series_A_B_C_D_E_9_Convertible1

Series A, B, C, D & E 9% Convertible Preferred Stock (Tables)	12 Months Ended			3 Months Ended				12 Months Ended
	Jul. 31, 2012			Oct. 31, 2012				Jul. 31, 2013
	Series B Convertible Preferred Stock			Series C Convertible Preferred Stock				Series E Convertible Preferred Stock
Fair value of Accounting allocation of initial proceeds	The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:			The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:				The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:
	Accounting allocation of initial proceeds			Accounting allocation of initial proceeds				Accounting allocation of initial proceeds
		Net proceeds	$1,975,000	Net proceeds	$	725,000		Net proceeds	$	1,165,000
		Derivative warrant liability fair value	(1,811,746)	Derivative warrant liability fair value		(624,797	)	Derivative warrant liability fair value		(1, 189,744)
		Make-whole payments liability	(540,000)	Make whole payments liability		(202,500	)	Derivative additional investment rights fair value		(1,264,683	)
		Deemed dividend	$(376, 746)	Deemed dividend	$	(102,297	)	Make whole payments liability		(330,750	)
								Deemed dividend	$	(1,620,177	)

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	12 Months Ended
	Jul. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Changes in value of derivative warrant liability	The following summarizes the changes in the value of the derivative warrant liability from August 1, 2011 until July 31, 2013:
		Value	No. of Warrants
	Balance at August 1, 2011 – Derivative warrant liability	$   8,745,508	80,234,017
	Exercise of warrants classified as derivative liability	-7,230,734	(49,863,260)
	Additional warrants issued in February 2012 financing	1,811,746	13,333,333
	Additional warrants from price protection features of existing warrants	1,548,813	11,444,440
	Decrease in fair value of derivative warrant liability	(793,706)	n/a
	Balance at July 31, 2012 – Derivative warrant liability	$   4,081,627	55,148,530
	Additional warrants issued in August 2012 financing	624,797	9,375,000
	Additional warrants issued in December 2012 financing	762,355	24,999,999
	Additional warrants issued in June 2013 financing	1,189,744	40,833,335
	Additional warrants from price protection features of existing warrants	7,484,550	236,219,094
	Exercise of warrants	-5,629,130	-145,888,421
	Decrease in fair value of derivative warrant liability	-3,279,650	n/a
	Balance at July 31, 2013 – Derivative warrant liability	$  5,234,293	220,687,537
Fair Value Assumptions Used in Accounting for Derivative Warrant Liability	The key inputs used in the July 31, 2013 and July 31, 2012 fair value calculations were as follows:
			July 31, 2013			July 31, 2012
	Current exercise price		$	0.03		$	0.15
	Time to expiration			3.5 years			3.9 years
	Risk-free interest rate			0.49	%		0.45	%
	Estimated volatility			85	%		104	%
	Dividend			-0-			-0-
	Stock price at period end date		$	0.035		$	0.093
Fair Value Assumptions Used in Accounting for Derivative Additional Investment Rights Liability	The key inputs used in the fair value calculation at July 31, 2013 were as follows:
			July 31, 2013
	Underlying number of units of convertible preferred stock			1,225
	Underlying number of warrants			40,833,335
	Current exercise price of warrants		$	0.03
	Current conversion price of preferred stock		$	0.03
	Time to expiration			0.88 years
	Risk-free interest rate			0.11	%
	Estimated volatility			114	%
	Dividend			-0-
	Stock price		$	0.035

Stockholders_DeficiencyEquity_

Stockholdersb (Deficiency)/Equity (Tables)	12 Months Ended
	Jul. 31, 2013
Equity [Abstract]
Warrants to purchase common stock outstanding	As of July 31, 2013, the Company has the following warrants to purchase common stock outstanding:
	Number of Shares		Warrant Exercise			Warrant
	To be Purchased		Price per Share			Expiration Date
		8,470,661	$	0.76		15-Dec-14
		3,413,928	$	0.79		4-Feb-15
		300,000	$	0.39	(average)	9-Feb-15
		200,000	$	1.25		7-Mar-15
		5,157,813	$	1		15-Mar-15
		102,016,744	$	0.03		March 31, 2016*
		2,508,560	$	0.03		July 11, 2016*
		27,272,720	$	0.03		September 30, 2016*
		7,500,000	$	0.03		February 1, 2017*
		16,389,512	$	0.03		August 10, 2017*
		24,166,666	$	0.03		December 12, 2017*
		40,833,335	$	0.03		June 17, 2018*
		238,229,939
	* Subject to price protection provisions as described below.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Jul. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Fair value of options granted	The following is the average of the data used to calculate the fair value for the options granted in the fiscal years ended July 31, 2011:
		Risk-Free			Expected		Expected			Expected
		Interest Rate			Life (Years)		Volatility			Dividends
	31-Jul-11		0.13	%		5		101	%		-0-
Common stock options granted, forfeited or expired and exercised	The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:
					Weighted Average
					Exercise Price
		Options			per Share
	Outstanding - August 1, 2010		7,465,638		$	0.49
	Granted		3,300,000		$	0.28
	Forfeited or expired		(2,848,704	)	$	0.41
	Exercised		(576,752	)	$	0.001
	Outstanding - July 31, 2011		7,340,182		$	0.46
	Granted		5,851,696		$	0.001
	Forfeited or expired		(912,250	)	$	0.65
	Exercised		(1,299,994	)	$	0.001
	Outstanding - July 31, 2012		10,979,634		$	0.26
	Granted		24,532,719		$	0.001
	Forfeited or expired		(630,778	)	$	0.75
	Exercised		(5,180,378	)	$	0.001
	Outstanding - July 31, 2013		29,701,197		$	0.08
	Exercisable - July 31, 2013		29,641,197		$	0.08
Non-vested common stock options granted, vested and forfeited	The following is a summary of the non-vested common stock options granted, vested and forfeited under the Plan:
					Weighted Average
					Grant Date
		Options			Fair Value
	Outstanding - August 1, 2012		172,500		$	0.46
	Granted		24,532,719		$	0.001
	Vested		(24,618,969	)	$	0.016
	Forfeited		(26,250	)	$	0.46
	Outstanding - July 31, 2013		60,000		$	0.46
Information on stock options outstanding	The following table summarizes information on stock options outstanding at July 31, 2013:
		Options Outstanding
							Weighted
		Number			Weighted		Average
		Outstanding			Average		Remaining			Aggregate
	Range of	at			Exercise		Life			Intrinsic
	Exercise Price	July 31, 2013			Price		(Years)			Value
	$0.00		24,446,197		$	0.001		4.49
	$0.19 - $0.38		3,150,000		$	0.28		2.6
	$0.39 - $0.58		200,000		$	0.56		1.24
	$0.59 - $0.77		1,485,000		$	0.63		4.31
	$0.78 - $0.96		420,000		$	0.94		1.24
			29,701,197		$	0.08		4.21		$	812,259
		Options Exercisable
							Weighted
		Number			Weighted		Average
		Outstanding			Average		Remaining			Aggregate
	Range of	at			Exercise		Life			Intrinsic
	Exercise Price	July 31, 2013			Price		(Years)			Value
	$0.001 - $0.18		24,446,197		$	0.001		4.49
	$0.19 - $0.38		3,150,000		$	0.28		2.6
	$0.39 - $0.58		200,000		$	0.56		1.24
	$0.59 - $0.77		1,425,000		$	0.63		4.44
	$0.78 - $0.96		420,000		$	0.94		1.24
			29,641,197		$	0.08		4.22		$	812,259
Intrinsic value of stock options		For the Year Ended July 31,
		2013			2012		2011
	Weighted Average Grant Date Fair Value of Options Granted	$	0.033		$	0.09	$	0.21
	Aggregate Intrinsic Value of Options Exercised	$	178,040		$	119,214	$	166,681
	Cash Received for Exercise of Stock Options	$	5,180		$	1,299	$	577
	The intrinsic value is calculated as the difference between the market value as of July 31, 2012, 2011 and 2010 and the exercise price of the shares on the respective dates.

Supplemental_Disclosure_of_Cas1

Supplemental Disclosure of Cash Flow Information (Tables)	12 Months Ended
	Jul. 31, 2013
Supplemental Cash Flow Elements [Abstract]
Supplemental disclosure of cash flow information
		For the Years Ended July 31,
		2013		2012		2011
	Cash paid during the year for:
	Interest	$	327,722	$	592,525	$	208,906
	Income taxes	$	—	$	—	$	—
	Disclosure of non-cash investing and financing activities:
	Year Ended July 31, 2013
	Issuance of common stock as payment of dividends on preferred stock	$	886,950
	Year Ended July 31, 2012
	Issuance of common stock as payment of dividends on preferred stock	$	485,190
	Year Ended July 31, 2011
	Issuance of common stock as payment of dividends on preferred stock	$	347,760
	Issuance of common stock as satisfaction of accounts payable and accrued expenses	$	1,110,867

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Jul. 31, 2013
Segment Reporting [Abstract]
Segment Information	The regions and countries in which the Company had identifiable assets and revenues are presented in the following table. Identifiable assets are those that can be directly associated with a geographic area.
		2013		2012
	Identifiable Assets
	Canada	$	2,825,894	$	2,350,818
	United States		2,026,969		2,293,556
	Middle East, North Africa (MENA)		—		—
	Total	$	4,852,863	$	4,644,374
		2013		2012		2011
	Revenue
	Canada	$	—	$	23,067	$	61,111
	United States		—		5,584		60,867
	Middle East, North Africa (MENA)		—		—		169,650
	Total	$	—	$	28,651	$	291,628

Quarterly_Information_Tables

Quarterly Information (Tables)	12 Months Ended
	Jul. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Quarterly information (unaudited)		Q1	Q2	Q3	Q4
	Fiscal Year July 31, 2013:
	Revenues, net	$               -0-	$               -0-	$               -0-	$               -0-
	Operating Loss	$ (1,940,031)	$ (1,290,780)	$ (1,433,640)	$ (1,464,908)
	Net Income/(Loss)	$   (656,199)	$ (5,640,985)	$  1,297,448	$ (3,554,586)
	Net Loss available to common stockholders	$   (758,496)	$ (5,640,985)	$  1,297,448	$ (5,174,763)
	Net Loss per share	$          0.002	$       (0.015)	$          0.003	$       (0.007)
	Fiscal Year July 31, 2012:
	Revenues, net	$         9,931	$          4,958	$          7,012	$      6,750
	Operating Loss	$ (3,469,778)	$ (1,786,231)	$ (2,466,270)	$ (2,301,769)
	Net Income/(Loss)	$      336,354	$ (9,118,651)	$      867,857	$ (1,575,838)
	Net Loss available to common stockholders	$      336,354	$ (9,118,651)	$      491,111	$ (1,575,838)
	Net Loss per share	$          0.001	$       (0.028)	$          0.003	$       (0.005)

Organization_and_Business_Deta

Organization and Business (Details Narrative) (USD $)	12 Months Ended
	Jul. 31, 2013
Accounting Policies [Abstract]
Upfront license fees	$600,000

Going_Concern_Details_Narrativ

Going Concern (Details Narrative) (USD $)	Jul. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit, approximate estimate	($368,000,000)
Working capital deficiency	-6,700,000

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended			213 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2013	Dec. 17, 2004
Accounting Policies [Abstract]
Minority interest in consolidated subsidiaries, less than:					100.00%
Ownership in all consolidated subsidiaries					100.00%
Write down of certain patents		$440,780		$1,353,976
Write down or disposal of certain long-lived assets		2,945,079	35,878
Deferred revenue	224,843	263,125		224,843
Grant revenue received, recorded as deferred revenue	$0	$0	$488,959	$0
Tax benefit sustained upon settlement, minimum	50.00%

Longlived_Assets_Property_and_

Long-lived Assets - Property and Equipment (Details) (USD $)	Jul. 31, 2013	Jul. 31, 2012
Property, Plant and Equipment, Gross	$507,939	$1,569,088
Less: Accumulated Depreciation	422,533	864,410
Property and Equipment, Net	85,406	704,678
Land
Property, Plant and Equipment, Gross	0	140,450
Building and Improvements
Property, Plant and Equipment, Gross	117,898	934,668
Furniture and Fixtures
Property, Plant and Equipment, Gross	23,452	47,794
Office Equipment
Property, Plant and Equipment, Gross	38,690	52,395
Lab Equipment
Property, Plant and Equipment, Gross	$327,899	$393,781

Longlived_Assets_Assets_Held_f

Long-lived Assets - Assets Held for Investment, Net (Details) (USD $)	Aug. 14, 2013	Jul. 31, 2013	Mar. 31, 2013	Sep. 30, 2012	Jul. 31, 2012	Jul. 30, 2012	Apr. 30, 2012	Aug. 31, 2011
Property, Plant and Equipment [Abstract]
Assets Held For Investment		$930,726			$1,179,276
Less: Accumulated Depreciation		289,954			320,899
Assets Held for Investment, Net	$699,248	$640,772	$169,566	$585,064	$858,377	$107,203	$1,783,932	$1,029,435

Longlived_Assets_Details_Narra

Long-lived Assets (Details Narrative) (USD $)	0 Months Ended	1 Months Ended					2 Months Ended	12 Months Ended
	Aug. 14, 2013	Aug. 31, 2013	Mar. 31, 2013	Sep. 30, 2012	Jul. 31, 2012	Aug. 31, 2011	Apr. 30, 2012	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 30, 2012
Property, Plant and Equipment [Abstract]
Depreciation expense								$41,890
Depreciation expense on assets held for investment								30,764	74,070	141,686
Gross proceeds from sale of real estate	926,000		256,835	1,579,189	342,862	1,669,115	2,865,682	221,399
Property, net book value	699,248		169,566	585,064	858,377	1,029,435	1,783,932	640,772	858,377		107,203
Gain on sale of real estate			87,682	994,125	235,659		1,081,750
Partial discharge of mortgage			216,810
Legal fees, interest, penalties from sale of real estate, approximation			13,000
Net proceeds from sale of real estate	209,000		27,025	1,028,780		1,009,827	2,190,952	1,081,807	1,957,089	0
Principal of mortgage discharged completely upon sale		617,665		480,951		659,288	571,680
Income from properties held for investment					249,127			163,358	249,127	349,458
Rental expenses									$135,172	$233,516
Properties held for investment, interest rate								9.75%

Patents_Costs_and_accumulated_

Patents - Costs and accumulated amortization of patents (Details) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012
Accounting Policies [Abstract]
Patents	$5,657,455	$5,587,790
Less: Accumulated Amortization	3,338,039	2,953,332
Patents, Net	$2,319,416	$2,634,458
Weighted Average Life	8 years 7 months 6 days	9 years 4 months 24 days

Patents_Details_Narrative

Patents (Details Narrative) (USD $)	12 Months Ended			213 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2013	Jul. 31, 2018	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2014
Accounting Policies [Abstract]
Amortization expense, patents	$391,777	$441,087	$430,650	$391,777
Amortization expense, patents, next year									274,000
Amortization expense, patents, year two								274,000
Amortization expense, patents, year three							274,000
Amortization expense, patents, year four						274,000
Amortization expense, patents, year five					274,000
Write-off of abandoned patents		$440,780		$1,353,976

Income_Taxes_Deferred_income_t

Income Taxes - Deferred income taxes (Details) (USD $)	Jul. 31, 2013	Jul. 31, 2012
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$87,541,552	$85,428,939
Other temporary differences	800,989	627,656
Total Deferred Tax Assets	88,342,541	86,056,595
Valuation Allowance	-88,098,860	-85,579,584
Intangible assets	-386,320	-378,672
Other temporary differences	142,639	-98,339
Total Deferred Tax Liabilities	-243,681	-477,011
Net Deferred Income Taxes

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of effective tax rate (Details)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Income Tax Disclosure [Abstract]
Federal statutory rate	-34.00%	-34.00%	-34.00%
Imputed interest income on intercompany receivables from foreign subsidiaries	6.00%	5.00%	3.00%
Nondeductible or non-taxable items	1.30%	4.00%	-4.00%
Change in Canadian NOL carryforwards due to future tax rate changes	0.00%	0.00%	20.00%
Other temporary differences	-14.00%	18.00%	18.00%
Change in valuation allowance	29.00%	-3.00%	-3.00%
Effective tax rate

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Pretax losses arising from domestic operations	$8,025,582	$8,040,033	$15,060,207
Pretax losses arising from foreign operations	528,741	1,450,244	6,615,660
Canadian effective tax rate	6.00%	5.00%	3.00%
Generex Pharmaceuticals, Inc
NOL carryforwards, expiring through 2033	44,924,097
Antigen Express, Inc
NOL carryforwards, expiring through 2033	$23,362,008
Maximum
Canadian effective tax rate			36.12%
Minimum
Canadian effective tax rate			26.50%

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Details) (USD $)	Jul. 31, 2013	Jul. 31, 2012
Payables and Accruals [Abstract]
Accounts Payable & Accruals -General and Administrative	$3,447,618	$3,556,160
Accounts Payable & Accruals - Research and Development	3,557,184	2,691,192
Accounts Payable & Accruals - Selling and Marketing	328,629	290,534
Accrued Make Whole Payments on Convertible Preferred Stock (see Note 9)	251,100	402,300
Executive Compensation and Directors' Fees Payable	76,703	75,466
Total	$7,661,234	$7,015,652

Commitments_and_Contingent_Lia2

Commitments and Contingent Liabilities - Aggregate minimum commitments under non-cancelable operating leases (Details) (USD $)	Jul. 31, 2012
Commitments and Contingencies Disclosure [Abstract]
2014	$152,094
2015	106,205
2016 and thereafter
Total Minimum Lease Payments	$258,299

Commitments_and_Contingent_Lia3

Commitments and Contingent Liabilities (Details Narrative) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2011

Jul. 20, 2001

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2011

20-May-11

Jul. 31, 2011

Jul. 31, 2011

Jul. 31, 2012

Nov. 16, 2012

Jul. 31, 2012

Jul. 31, 2013

Jul. 31, 2013

President

Antigen Employees

Termination Of Employee

Termination Of Employee

Breach of contract and detinue

Punitive Damages

Sale Of Estate

Damages for Unpaid Invoices

Damages for Unpaid Invoices

Clinical Study Agreement

Insurance Policy

Lease Expense

$153,000

$185,000

$210,000

Minimum units purchased, each year

10,000,000

Commitments with Antigen

226,000

108,000

Monthly gross rent, including taxes and expenses

6,800

Shares of CBI owned by former business associate

50.00%

Shares of CBI owned by Company

50.00%

Value of damages sought

7,000,000

550,000

50,000

1,730,000

429,000

Counterclaim proceeding

2,300,000

200,000

Lawsuit filing date

20-May-11

1-Jun-11

31-Aug-11

31-Dec-11

Name of Plaintiff

Ms. Perri

Golden Bull Estates

Antonio Perri

Vendor

Settlement of litigation

125,000

Annual salary

$475,000

$371,305

LongTerm_Debt_Longterm_debt_De

Long-Term Debt - Long-term debt (Details) (USD $)	24 Months Ended
	Jul. 31, 2013	Jul. 31, 2012
Total Debt	$617,665	$1,664,161
Less Current Maturities of Long-Term Debt	617,665	1,222,746
Total Long-Term Debt		441,415
Second Mortgage, due January 2013
Mortgage payable, interest per annum	10.00%	10.00%
Mortgage payable, monthly interest payments	9,807
Total Debt	0	1,181,461
First Mortgage, due May 2015
Mortgage payable, interest per annum	6.75%	6.75%
Mortgage payable, monthly interest payments	6,014
Total Debt	0	482,700
Second Mortgage, due November 2013
Mortgage payable, interest per annum	9.75%	9.75%
Mortgage payable, monthly interest payments	6,771
Total Debt	$617,665	$0

LongTerm_Debt_Details_Narrativ

Long-Term Debt (Details Narrative) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Debt Disclosure [Abstract]
Interest expense on long-term debt	$196,101	$568,424	$205,539

Fair_value_of_Accounting_alloc

Fair value of Accounting allocation of initial proceeds - Series A, B, C, D & E 9% Convertible Preferred Stock (Details) (USD $)	12 Months Ended						213 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2004	Jul. 31, 2003	Jul. 31, 2002	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Jul. 31, 2013
								Series B Convertible Preferred Stock	Series C Convertible Preferred Stock	Series E Convertible Preferred Stock
Net proceeds	$2,615,000	$1,975,000	$2,315,000				$18,920,000	$1,975,000	$725,000	$1,165,000
Derivative warrant liability fair value								-1,811,746	-624,797	-1,189,744
Derivative additional investment rights fair value										-1,264,683
Make whole payments liability								-540,000	-202,500	-330,750
Deemed dividend	($1,722,474)	($376,746)	($766,417)	($810,003)	($764,154)	($720,900)		($376,746)	($102,297)	($1,620,177)

Series_A_B_C_D_E_9_Convertible2

Series A, B, C, D & E 9% Convertible Preferred Stock (Details Narrative) (USD $)	12 Months Ended				213 Months Ended	12 Months Ended	4 Months Ended	8 Months Ended	12 Months Ended	4 Months Ended	8 Months Ended	12 Months Ended			12 Months Ended		35 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2005	Jul. 31, 2013	Jul. 31, 2013	Dec. 10, 2012	Jul. 31, 2013	Jul. 31, 2013	Dec. 10, 2012	Jul. 31, 2013	Jul. 31, 2013	Jul. 31, 2013	Mar. 28, 2013	Jun. 17, 2017	Jul. 31, 2013	Jun. 17, 2016	Jun. 30, 2013
						Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Series B Convertible Preferred Stock	Series B Convertible Preferred Stock	Series C Convertible Preferred Stock	Series C Convertible Preferred Stock	Series C Convertible Preferred Stock	Series D Convertible Preferred Stock	Series D Convertible Preferred Stock	Series E Convertible Preferred Stock	Series E Convertible Preferred Stock	Series E Convertible Preferred Stock	Additional Units
Convertible preferred stock, shares authorized						5,500	792	2,000	2,000	650	750	750	750			2,450
Convertible preferred stock, cumulative percentage of interest						9.00%		9.00%	9.00%		9.00%	9.00%	9.00%			9.00%
Convertible preferred stock, par value (in dollars per share)						$1,000		$1,000	$1,000		$1,000	$1,000	$1,000			$1,000		$1,000
Convertible preferred stock, shares issued						2,575		2,000	2,000		750	750	750			1,225
Common shares attributable to conversion of preferred stock						17,166,666	9,897,500	26,393,333	13,333,333	8,125,000	21,666,666	9,375,000	24,999,999			40,833,335
Common stock issued upon conversion of preferred stock						17,166,666		38,520,832	38,520,832		22,916,665	22,916,665	24,999,999			9,833,334
Common stock issued as "make-whole payments" on conversions of preferred stock						6,129,666		14,819,679	14,819,679		6,664,863	6,664,863	7,825,191			2,654,999
Convertible preferred stock conversion price							$0.08	$0.03		$0.03		$0.08
Net proceeds from financing	$2,615,000	$1,975,000	$2,315,000		$18,920,000				$1,975,000		$725,000		$725,000			$1,165,000
Preferred stock, face value														750,000
Common stock, effective conversion price																	$0.03
Preferred stock, dividend rate percentage															3.00%		9.00%
Increased preferred stock dividend rate percentage															0.18
Conversion of preferred stock				14,310,057												295	270
Conversion of stock, amount converted																	1,000
Warrants issued to investors																40,833,335
Aggregate subscription amount, maximum																		1,225,000
"Make-whole payments", value																330,750
Accounts payable and accrued expenses																$251,100

Changes_in_value_of_derivative

Changes in value of derivative warrant liability - Derivative Liabilities (Details) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012
Balance - Derivative warrant liability Value	$4,081,627	$8,745,508
No. of Warrants - Derivative warrant liability	55,148,530	80,234,017
Exercise of Warrants	-5,629,130	-7,230,734
Warrants Exercised	-145,888,421	-49,863,260
Decrease in fair value of derivative warrant liability	-3,279,650	-793,706
Balance - Derivative warrant liability Value	5,234,293	4,081,627
No. of Warrants - Derivative warrant liability	220,687,537	55,148,530
Feb-12
Additional warrants issued		1,811,746
Warrants Issued		13,333,333
Price Protection
Additional warrants issued	7,484,550	1,548,813
Warrants Issued	236,219,094	11,444,440
Aug-12
Additional warrants issued	624,797
Warrants Issued	9,375,000
Dec-12
Additional warrants issued	762,355
Warrants Issued	24,999,999
Jun-13
Additional warrants issued	$1,189,744
Warrants Issued	40,833,335

Fair_Value_Assumptions_Used_in

Fair Value Assumptions Used in Accounting for Derivative Warrant Liability - Derivative Liabilities (Details 1) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jun. 04, 2013	Mar. 05, 2013	Feb. 05, 2013	Jun. 06, 2012
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Current exercise price	$0.03	$0.15
Time to expiration	3 years 6 months	3 years 10 months 24 days
Risk-free interest rate	0.49%	0.45%
Estimated volatility	85.00%	85.00%
Dividend	0.00%	0.00%
Stock price at period end date	$0.04	$0.09	$0.03	$0.03	$0.04	$0.09

Fair_Value_Assumptions_Used_in1

Fair Value Assumptions Used in Accounting for Derivative Additional Investment Rights Liability - Derivative Liabilities (Details 2) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jun. 04, 2013	Mar. 05, 2013	Feb. 05, 2013	Jun. 06, 2012
Current exercise price of warrants	$0.03	$0.15
Time to expiration	3 years 6 months	3 years 10 months 24 days
Risk-free interest rate	0.49%	0.45%
Estimated volatility	85.00%	85.00%
Dividend	0.00%	0.00%
Stock price	$0.04	$0.09	$0.03	$0.03	$0.04	$0.09
Additional Investment Rights
Underlying number of units of convertible preferred stock	1,225
Underlying number of warrants	40,833,335
Current exercise price of warrants	$0.03
Current conversion price of preferred stock	$0.03
Time to expiration	10 months 17 days
Risk-free interest rate	0.11%
Estimated volatility	114.00%
Dividend	0.00%
Stock price	$0.04

Derivative_Liabilities_Details

Derivative Liabilities (Details Narrative) (USD $)	12 Months Ended			213 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2013
Recognition of loss due to derivative liability	($3,140,259)	($1,081,440)	$2,220,916	($3,856,236)	[1]
Additional investment rights		841,333
Issuing Additional Warrants
Derivative warrants weighted average remaining life	3 years 5 months 15 days
Recognition of loss due to derivative liability	3,148,782	1,081,440
Fair Value of Warrants
Fair value of derivative liability	5,234,293	4,081,627		5,234,293
Additional investment rights	1,256,160
Recognition of Gain
Additional investment rights	$8,523
[1]	Includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to July 31, 2013" column. See Note 10 - Derivative Liabilities.

Warrants_to_purchase_common_st

Warrants to purchase common stock outstanding - Stockholders' (Deficiency)/Equity (Details) (USD $)

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2011

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Warrant Expiration Date 15 December 2014

Warrant Expiration Date 4 February 2015

Warrant Expiration Date 12 December 2017

Warrant Expiration Date 9 February 2015

Warrant Expiration Date 7 March 2015

Warrant Expiration Date 15 March 2015

Warrant Expiration Date 31 March 2016

Warrant Expiration Date 11 July 2016

Warrant Expiration Date 30 September 2016

Warrant Expiration Date 1 February 2017

Warrant Expiration Date 10 August 2017

Warrant Expiration Date 12 December 2017

Warrant Expiration Date 17 June 2018

Number of Shares To be Purchased

220,687,537

55,148,530

80,234,017

8,470,661

24,166,666

300,000

200,000

5,157,813

102,016,744

2,508,560

27,272,720

7,500,000

16,389,512

24,166,666

40,833,335

Warrant Exercise Price per Share

$0.76

$0.79

$0.39

$1.25

$1

$0.03

$0.03

$0.03

$0.03

$0.03

$0.03

$0.03

Warrant Expiration Date

15-Dec-14

4-Feb-15

9-Feb-15

7-Mar-15

15-Mar-15

31-Mar-16

11-Jul-16

30-Sep-16

1-Feb-17

10-Aug-17

12-Dec-17

17-Jun-18

Stockholders_DeficiencyEquity_1

Stockholders' (Deficiency)/Equity (Details Narrative) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Outstanding warrants, weighted average exercise price	$0.09
Outstanding warrants, weighted average remaining life (in years)	3 years 3 months 21 days
Number of shares to be purchased	220,687,537	55,148,530	80,234,017
Number of shares to be purchased, exercise price	$0.03	$0.15
Common stock issued and outstanding	580,329,160	354,161,297
Estimated value of warrants	$5,234,293
Series B Convertible Preferred Stock [Member]
Convertible preferred stock, shares issued		1,490
Convertible preferred stock, shares outstanding		1,490
Convertible preferred stock, cumulative percentage of interest		9.00%
Warrant Expiration Date 31 March 2016
Number of shares to be purchased	102,016,744
Number of shares to be purchased, exercise price	$0.03
Warrant Expiration Date 11 July 2016
Number of shares to be purchased	2,508,560
Number of shares to be purchased, exercise price	$0.03
Warrant Expiration Date 30 September 2016
Number of shares to be purchased	27,272,720
Number of shares to be purchased, exercise price	$0.03
Warrant Expiration Date 1 February 2017
Number of shares to be purchased	7,500,000
Number of shares to be purchased, exercise price	$0.03
Warrant Expiration Date 10 August 2017
Number of shares to be purchased	16,389,512
Number of shares to be purchased, exercise price	$0.03
Warrant Expiration Date 12 December 2017
Number of shares to be purchased	24,166,666
Number of shares to be purchased, exercise price	$0.03
Warrant Expiration Date 17 June 2018
Number of shares to be purchased	40,833,335
Number of shares to be purchased, exercise price	$0.03
Board Approved Equity Program
Common stock issued and outstanding	5,608,926
Percentage of common stock issued and outstanding	5.00%
Approved In Good Faith
Common stock issued and outstanding	11,217,853
Percentage of common stock issued and outstanding	10.00%
Preferred Stock
Convertible preferred stock, shares authorized	1,000,000
Convertible preferred stock, par value (in dollars per share)	$0.00

Fair_value_of_options_granted_

Fair value of options granted - Stock-Based Compensation (Details) (USD $)	12 Months Ended
	Jul. 31, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-Free Interest Rate	0.13%
Expected Life (Years)	5 years
Expected Volatility	101.00%
Expected Dividends	$0

Common_stock_options_granted_f

Common stock options granted, forfeited or expired and exercised - Stock-Based Compensation (Details 1) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2010
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Outstanding	29,701,197	7,340,182	7,465,638
Options Granted	24,532,719	5,851,696	3,300,000
Options Forfeited or expired	-630,778	-912,250	-2,848,704
Options Exercised	-5,180,378	-1,299,994	-576,752	0
Options Outstanding	29,701,197	29,701,197	7,340,182	7,465,638
Options Exercisable	29,641,197
Weighted Average Exercise Price per Share	$0.08	$0.46	$0.49
Weighted Average Exercise Price per Share, Granted	$0.00	$0.00	$0.28
Weighted Average Exercise Price per Share, Forfeited or expired	$0.75	$0.65	$0.41
Weighted Average Exercise Price per Share, Exercised	$0.00	$0.00	$0.00
Weighted Average Exercise Price per Share, Outstanding		$0.08	$0.46	$0.49
Weighted Average Exercise Price per Share, Exercisable	$0.08

Nonvested_common_stock_options

Non-vested common stock options granted, vested and forfeited - Stock-Based Compensation (Details 2) (USD $)	12 Months Ended
	Jul. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Outstanding	172,500
Options Granted	24,532,719
Options Vested	-24,618,969
Options Forfeited	-26,250
Options Outstanding	60,000
Weighted Average Grant Date Fair Value Outstanding	$0.46
Weighted Average Grant Date Fair Value Granted	$0.00
Weighted Average Grant Date Fair Value Vested	$0.02
Weighted Average Grant Date Fair Value Forfeited	$0.46
Weighted Average Grant Date Fair Value Outstanding	$0.46

Information_on_stock_options_o

Information on stock options outstanding - Stock-Based Compensation (Details 3) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2013	Jul. 31, 2011	Jul. 31, 2010
Options Outstanding	29,701,197	29,701,197	7,340,182	7,465,638
Weighted Average Exercise Price per Share	$0.08		$0.46	$0.49
Options Weighted Average Remaining Life (Years)	4 years 2 months 15 days
Options Aggregate Intrinsic Value	$812,259
Options Exercisable	29,641,197
Weighted Average Exercise Price per Share Exercisable	$0.08
Options Weighted Average Remaining Life (Years)	4 years 2 months 16 days
Options Aggregate Intrinsic Value	$812,259
Exercise Price 0.001
Options Range of Exercise Price	$0.00
Options Range of Exercise Price	$0.00
Options Outstanding		24,446,197
Weighted Average Exercise Price per Share		$0.00
Options Weighted Average Remaining Life (Years)	4 years 5 months 26 days
Options Exercisable	24,446,197
Weighted Average Exercise Price per Share Exercisable	$0.00
Options Weighted Average Remaining Life (Years)	4 years 5 months 26 days
Exercise Price 0.19 to 0.38
Options Range of Exercise Price	$0.19
Options Range of Exercise Price	$0.38
Options Outstanding		3,150,000
Weighted Average Exercise Price per Share		$0.28
Options Weighted Average Remaining Life (Years)	2 years 7 months 6 days
Options Exercisable	3,150,000
Weighted Average Exercise Price per Share Exercisable	$0.28
Options Weighted Average Remaining Life (Years)	2 years 7 months 6 days
Exercis Price 0.39 to 0.58
Options Range of Exercise Price	$0.39
Options Range of Exercise Price	$0.58
Options Outstanding		200,000
Weighted Average Exercise Price per Share		$0.56
Options Weighted Average Remaining Life (Years)	1 year 2 months 26 days
Options Exercisable	200,000
Weighted Average Exercise Price per Share Exercisable	$0.56
Options Weighted Average Remaining Life (Years)	1 year 2 months 26 days
Exercise Price 0.59 to 0.77
Options Range of Exercise Price	$0.59
Options Range of Exercise Price	$0.77
Options Outstanding		1,485,000
Weighted Average Exercise Price per Share		$0.63
Options Weighted Average Remaining Life (Years)	4 years 3 months 21 days
Options Exercisable	1,425,000
Weighted Average Exercise Price per Share Exercisable	$0.63
Options Weighted Average Remaining Life (Years)	4 years 3 months 21 days
Exercise Price 0.78 to 0.96
Options Range of Exercise Price	$0.78
Options Range of Exercise Price	$0.96
Options Outstanding		420,000
Weighted Average Exercise Price per Share		$0.94
Options Weighted Average Remaining Life (Years)	1 year 2 months 26 days
Options Exercisable	420,000
Weighted Average Exercise Price per Share Exercisable	$0.94
Options Weighted Average Remaining Life (Years)	1 year 2 months 26 days

Intrinsic_value_of_stock_optio

Intrinsic value of stock options - Stock-Based Compensation (Details 4) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted Average Grant Date Fair Value of Options Granted	$0.03	$0.09	$0.21
Aggregate Intrinsic Value of Options Exercised	$178,040	$119,214	$166,681
Cash Received for Exercise of Stock Options	$5,180	$1,299	$577

StockBased_Compensation_Detail

Stock-Based Compensation (Details Narrative) (USD $)	12 Months Ended		213 Months Ended							12 Months Ended
	Jul. 31, 2013	Jul. 31, 2011	Jul. 31, 2013	Jun. 04, 2013	Mar. 05, 2013	Feb. 05, 2013	Jul. 31, 2012	Jun. 06, 2012	Jul. 31, 2010	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2013	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
										Stock Options	Stock Options	Stock Options	Common Stock	Common Stock	Common Stock	Stock Option Plan 2001	Stock Option Plan 2006	Stock Option Plan 2006	Stock Options	Stock Options	Stock Options
Common stock reserved for future issuance																12,000,000	60,000,000
Common stock reserved for future awards																4,650,222	7,113,391
Share-based employee compensation										$837,753	$602,384	$936,465	$0	$130,544	$100,999
Outstanding options	29,701,197	7,340,182	29,701,197				29,701,197		7,465,638										29,701,197
Outstanding options, weighted average remaining contractual term										4 years 2 months 16 days
Unrecognized compensation cost	5,365		5,365
Cost expected to be recognized, weighted average period of time	2 months 12 days
Share based compensation for deferred salary and director fees																			24,532,719	5,851,696	3,300,000
Closing price of common stock	$0.04		$0.04	$0.03	$0.03	$0.04	$0.09	$0.09									$0.00	$0.00
Fair value of stock options granted			4,011,938									692,010
Fair value of stock options vested																					692,010
Grant date exercise price and current price of underlying stock																					$0.28
Options fair value assumptions, expected term		5 years										5 years
Options fair value assumptions, expected volatility rate		101.00%										101.30%
Options fair value assumptions, expected dividend payments		$0										$0
Risk-free interest rate		0.13%										0.13%

Qualifying_Therapeutic_Discove1

Qualifying Therapeutic Discovery Project Program (Details Narrative) (USD $)	12 Months Ended
	Jul. 31, 2011
Notes to Financial Statements
Cash grant awarded under Discovery Program	$488,959

Net_Loss_per_Share_Details_Nar

Net Loss per Share (Details Narrative)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Earnings Per Share [Abstract]
Antidilutive securities excluded from earnings per share, incremental shares	298,931,138	94,643,712	115,875,372

Supplemental_Disclosure_of_Cas2

Supplemental Disclosure of Cash Flow Information - Supplemental disclosure of cash flow information (Details) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Cash paid during the year for:
Interest	$327,722	$592,525	$208,906
Income taxes
Disclosure of non-cash investing and financing activities:
Issuance of common stock as payment of dividends on preferred stock	886,950	485,190	347,760
Issuance of common stock as satisfaction of accounts payable and accrued expenses			$1,110,867

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended								12 Months Ended			213 Months Ended
	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2013
Identifiable Assets	$4,852,863				$4,644,374				$4,852,863	$4,644,374		$4,852,863
Revenue	0	0	0	0	6,750	7,012	4,958	9,931		28,651	291,628	5,110,784
Canada
Identifiable Assets	2,825,894				2,350,818				2,825,894	2,350,818		2,825,894
Revenue										23,067	61,111
United States
Identifiable Assets	2,026,969				2,293,556				2,026,969	2,293,556		2,026,969
Revenue										5,584	60,867
Middle East, North Africa (MENA)
Identifiable Assets
Revenue											169,650
Identifiable Assets
Identifiable Assets	$4,852,863								$4,852,863			$4,852,863

Quarterly_Information_Quarterl

Quarterly Information - Quarterly information (unaudited) (Details) (USD $)	3 Months Ended								9 Months Ended	12 Months Ended																	213 Months Ended
	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 1996	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2010	Jul. 31, 2009	Jul. 31, 2008	Jul. 31, 2007	Jul. 31, 2006	Jul. 31, 2005	Jul. 31, 2004	Jul. 31, 2003	Jul. 31, 2002	Jul. 31, 2001	Jul. 31, 2000	Jul. 31, 1999	Jul. 31, 1998	Jul. 31, 1997	Jul. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Revenues, net	$0	$0	$0	$0	$6,750	$7,012	$4,958	$9,931			$28,651	$291,628															$5,110,784
Operating Loss	-1,464,908	-1,433,640	-1,290,780	-1,940,031	-2,301,769	-2,466,270	-1,786,231	-3,469,778		-6,129,359	-10,024,048	-24,533,082															-292,284,830
Net Income/(Loss)	-3,554,586	1,297,448	-5,640,985	-656,199		867,857	-9,118,651	336,354	-693,448	-8,554,322	-9,490,278	-21,675,867	-25,279,940	-45,812,228	-36,228,991	-23,504,958	-67,967,204	-24,001,735	-18,362,583	-13,261,764	-13,693,034	-27,097,210	-8,841,047	-6,239,602	-4,663,604	-1,379,024	-362,727,882
Net Loss available to common stockholders	($5,174,763)	$1,297,448	($5,640,985)	($758,496)	($1,575,838)	$491,111	($9,118,651)	$336,354		($10,276,796)	($9,867,024)	($22,442,284)															($367,888,576)
Net Loss per share	($0.01)	$0.00	($0.02)	$0.00	($0.01)	$0.00	($0.03)	$0.00		($0.02)	($0.03)	($0.08)

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	0 Months Ended	1 Months Ended				2 Months Ended	12 Months Ended
	Aug. 14, 2013	Mar. 31, 2013	Sep. 30, 2012	Jul. 31, 2012	Aug. 31, 2011	Apr. 30, 2012	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 30, 2012
Subsequent Events [Abstract]
Gross proceeds from sale of real estate	$926,000	$256,835	$1,579,189	$342,862	$1,669,115	$2,865,682	$221,399
Property, net book value	699,248	169,566	585,064	858,377	1,029,435	1,783,932	640,772	858,377		107,203
Net proceeds from sale of real estate	$209,000	$27,025	$1,028,780		$1,009,827	$2,190,952	$1,081,807	$1,957,089	$0